WO2005066241A1 - Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents - Google Patents

Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents Download PDF

Info

Publication number
WO2005066241A1
WO2005066241A1 PCT/US2004/041205 US2004041205W WO2005066241A1 WO 2005066241 A1 WO2005066241 A1 WO 2005066241A1 US 2004041205 W US2004041205 W US 2004041205W WO 2005066241 A1 WO2005066241 A1 WO 2005066241A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
poly
type
medical device
polymers
Prior art date
Application number
PCT/US2004/041205
Other languages
French (fr)
Inventor
Stephen D. Pacetti
Original Assignee
Advanced Cardiovascular Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cardiovascular Systems, Inc. filed Critical Advanced Cardiovascular Systems, Inc.
Priority to EP20040813517 priority Critical patent/EP1694743A1/en
Priority to JP2006545750A priority patent/JP2007518850A/en
Publication of WO2005066241A1 publication Critical patent/WO2005066241A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44Polyester-amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28Materials for coating prostheses
    • A61L27/34Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • A61L31/10Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31551Of polyamidoester [polyurethane, polyisocyanate, polycarbamate, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/31504Composite [nonstructural laminate]
    • Y10T428/31725Of polyamide

Definitions

  • PTCA Percutaneous transluminal coronary angioplasty
  • Stents are used not only mechanically, but also to provide biological therapy. Mechanically, stents act as scaffoldings, physically holding open and, if desired, expanding the vessel wall. Typically, stents compress for insertion through small vessels and then expand to a larger diameter once in position.
  • U. S. Patent No. 4,733,665, issued to Palmaz; U. S. Patent No. 4,800,882, issued to Gianturco; and U. S. Patent No. 4,886,062, issued to ' Wiktor disclose examples of PTCA stents.
  • Medicating the stent provides for pharmacological therapy. Medicated stents allow local drug administration at the diseased site.
  • One proposed method for medicating stents involves coating a polymeric carrier onto a stent surface. This method applies a solution that includes a solvent, a dissolved polymer, and a dissolved or dispersed drug to the stent. As the solvent evaporates, it leaves a drug impregnated, polymer coating on the stent.
  • This invention relates to biobeneficial copolymers, some of which are useful in medical device applications. Some of these medical devices are implantable within a mammalian body, such as in a body lumen or blood vessel.
  • biobeneficial is a description for any surface that bestows biological benefit to an implantable medical device without releasing drug(s).
  • the copolymers comprise at least two different blocks, at least one l block with the formula shown in Formula I, below
  • the Ll block can be as shown in Formula III, below.
  • the Ll blocks are the same or different.
  • R are the same or different for each occurrence and are 1-16 carbon (un)substituted, (un)branched alkyl or (un)substituted, (un)branched diol or triol oligomers.
  • k are the same or different ' for each Ll block ranging from 6 to 460.
  • the L2 blocks are the same or different, and j are the same or different for each L2 block ranging from 2 to 30.
  • Exemplary R include oligomers of ethylene glycol, propylene glycol (1,2- and 1,3 -substituted isomers), tetramethylene glycol (1,2-, 1,3-, 1,4-, and 2,3-substituted isomers), and hexamethylene glycol (1,2-, 1,3-, 1,4- 1,5-, 1,6-, 2,3-, 2,4-, 2,5-, 3,4-substituted isomers).
  • any of the preceding glycols will yield unbranched moieties when substituted at the first and last carbon atom and will yield branched moieties with other substitutions patterns.
  • Some embodiments are envisioned that use mixtures of polyols.
  • R can be (un)branched alkyl, alkenyl, or alkynyl moieties.
  • R-group is- specified as an ethylene or ethylene glycol unit.
  • the formula is intended to represent its genus with an R-groups as defined in this paragraph and is intended to represent the species with the specified R-group shown.
  • the above Ll block is written below in Formula IV with R defined as it would be if the polyether portion of the Ll block were selected to be PEG and the Ll portion is a- diamide.
  • Ll and L2 independently, represent linkages with the formula shown in Formula V, above.
  • Formula VI 0 II provided that if Y and Z are the same, they are not • c ° .
  • the heavy circle indicates the position at which Y or Z attaches to the phenyl ring of Ll or L2, respectively.
  • these polymers compose structural polymeric medical devices and compose coatings for polymeric, metallic, ceramic, glass, or composite medical devices.
  • these polymers can be mixed with other polymers, with drugs, or with both. Methods of making medical devices using these polymers are disclosed, as well.
  • This disclosure reveals a family of biobeneficial, polyamide-polyethylene-glycol polymers.
  • these polymers compose the base material for implantable medical devices.
  • implantable medical devices comprise these polymers.
  • these polymers compose implantable medical device coatings.
  • This polymer family comprises the reaction products of various reactants, wherein reactants comprise the following basic components: terephthalic acid (Formula VII, below) or a similar 1,4- difunctionally substituted benzyl group, amine-terminated polyethylene glycol or another group, as described below, and at least one aliphatic diamine.
  • 1,4- disubstituted phenyl or benzyl rings axe referred to or depicted.
  • such reference or depiction includes variations in which the phenyl or benzyl rings are additionally substituted at least at the 2, 3, 5, or 6 positions. Any substitution is allowed.
  • Invention embodiments contain amine-terminated polyethylene glycol, such as the ED series of Jeffamine polymers (from Huntsman Chemical) or mono-amine-terminated PEG (from Shearwater Polymers). These Jeffamine polymers have a polyethylene glycol backbone with some polypropylene glycol units at the chain ends. The polypropylene units contain the primary amine.
  • amine-terminated polyethylene glycol such as the ED series of Jeffamine polymers (from Huntsman Chemical) or mono-amine-terminated PEG (from Shearwater Polymers). These Jeffamine polymers have a polyethylene glycol backbone with some polypropylene glycol units at the chain ends. The polypropylene units contain the primary amine.
  • invention embodiments contain an aliphatic diamine, such as 1,2-ethanediamine (Formula VIII, below),
  • diamines are biocompatible in the unlikely event that in-vivo use causes their release.
  • the synthesis of invention polymers is straightforward using standard nylon polymerization techniques.
  • Other useful diamines are 1,5-pentanediamine, 1,6-heaxanediamine, and 1 ,6-diaminocyclohexane.
  • Embodiments that have branching from the diamine backbone are . within the scope of this description.
  • the diamine is selected from straight chain or branched, aliphatic diamino compounds where the amino groups are primary or secondary and the total number of carbons per diamine is 16 or less.
  • R can be polyethylene, polypropylene, polyisobutylene, polyis ⁇ prene, polybutene, poly(hexamethylene glycol), poly(tetramethylene glycol), or poly(propylene glycol), and R has a molecular weight of 26 to 500 Daltons.
  • R can be described as having an optional linkage between the R and the PEG. This linkage could be any of those shown in Structure Table I, above.
  • Some invention embodiments select the amine-terminated polyethylene glycol, or the aliphatic diamines, or both, to be primary amines.
  • One of ordinary skill in the art recognizes that similar chemistry would arise from using secondary amines for the amine-terminated polyethylene glycol or the aliphatic diamines.
  • This disclosure defines a linkage prepared using secondary amines as a "substituted amide linkage" shown in Formula XI, below:
  • Some invention embodiments select the amine-terminated polyethylene glycol or the aliphatic diamines or both to be secondary amines. On the other hand, some invention embodiments specifically exclude secondary amines from being the amine-terminated polyethylene glycol or the aliphatic diamines or both. Likewise, some invention embodiments exclude primary amines from- being the amine-terminated polyethylene glycol or the aliphatic diamines or both.
  • the biobeneficial component should also be bioabsorbable.
  • the biobeneficial component would ideally be biostable, as well. This is because the biobeneficial feature has both acute and chronic, long-term effects.
  • PEG for example, works by resisting protein adhesion and denaturation at the implant surface.
  • This disclosure reveals, among other embodiments, a biostable version of a polyester, biodegradable eopolyiher POLYACTIVE in which at least some replacement of the ester linkages by amide (or other) linkages occurs.
  • POLYACTIVE is a trade name of a PBT-PEG ' group of products and is available from IsoTisCorp. of.Holland.
  • the molar ratio between the units derived from ethylene glycol and the units derived from butylene terephthalate falls between about 0.01 :1 and about 1:1.
  • the molecular weight of the units derived from ethylene glycol can be between about 300 and about 10,000 Daltons.
  • the structure of POLYACTIVE is shown in Formula.XII, below.
  • k ranges from 4 to 230, or more narrowly, from 7 to 91.
  • the values of 1, m, and n constrain each other for a given molecular weight. LTherefore, the value of m is set to unity and the values of 1 and n will give the ratio of the two blocks and the total molecular weight. 1 ranges from 0.003 to 0.60, or more narrowly, from 0.01 to 0.45. And n ranges from 30 to 500, or more narrowly, from 100 to 375.
  • k ranges from 4 to 230, or more narrowly, from 7 to 91. 1 ranges from 0.005 to 2.0, or more narrowly, from 0.01 to 1.6. m is set at unity. And n ranges from 20 to 600, or more narrowly, from 40 to 450.
  • amide linkages replace all ester linkages in POLYACTIVE. Alternatively, in some embodiments, amide linkages replace 25-100 percent of the ester linkages; amide linkages replace 50-100 percent of the ester linkage; amide linkages replace 75- 100 percent of the ester linkages; amide linkages replace 95-100 percent of the ester linkages; or amide linkages replace 99-100 percent of the ester linkages.
  • 25-100 percent of the ester linkages remain after some amide linkage replacement; 50-100 percent of the ester linkage remain after some amide linkage replacement; 75 -100- percent of the ester linkages remain after some amide linkage replacement; 95-100 percent of the ester linkages remain after some amide linkage replacement; or 99-100 percent of the ester linkages remain after some amide linkage replacement.
  • This amide substitution removes the ester linkage from POLYACTIVE or reduces the number of ester linkages compared with the number in POLYACTIVE.
  • Ester linkages hydrolyze in-vivo. But amide linkages are many times more stable.
  • Some invention embodiments select the polymer formulation such that the resulting polymer is substantially broken down by the in vivo environment in an amount of time of from 1 to 24 months; alternatively, in an amount of time of from 2 to 18 months; alternatively, in an amount of time of from 3 to 12 months.
  • substantially broken down means that non- invasive diagnostic procedures as skilled artisans normally employ cannot detect the polymer in vivo.
  • biocompatible means that the material passes or is found acceptable by at least one of the following in vitro tests, as specified by ISO 10993.
  • in vitro tests would include ISO 10993-5 cytotoxicity (this is a L929 mouse fibroblast test using extracts of the material); ISO 10993-4 hemocompatibility (this is a specific test for thrombosis, coagulation, platelet consumption, hematology, and immunology); ISO 10993-3 genotoxicity (this includes the Ames test, mouse cell lymphoma test, and Chinese hamster ovary cell test).
  • invention polymers comprise at least one Ll block, shown in Formula III, above and at least one L2 block, shown in Formula II, above.
  • the Ll blocks are the same or different and k are the same or different for each Ll block and range from 6 to 460.
  • the L2 blocks are the same or different and j are the same or different for each L2 block and range from 2 to 30.
  • k, 1, m, n take the above-disclosed values, m equals one, leaving 1 to define the ratio of 1 to m and n to define to total molecular weight, j ranges from 2 to 30, or more narrowly, from 2 to 6.
  • Ll and L2 independently have Formula V, as shown above. Some embodiments independently select Ll and L2, as indicated above. In other embodiments, Ll and L2 are purposely chosen to be the same. Other embodiments purposely choose Ll and L2 to be different from each other. In any of these embodiments, appropriate selection of Y and Z yields Y and Z that are both more resistant to in vivo hydrolysis than an ester moiety, appropriate selection of Y and Z yields Y and Z in which one or the other is more resistant to in vivo hydrolysis than an ester moiety, or appropriate selection of Y and Z yields Y and Z that are both less resistant to in vivo hydrolysis than an ester moiety.
  • any amides selected for Y or Z would be substituted amides.
  • Some invention embodiments specifically exclude Y or Z equal to one of or any combination of esters, amides, urethanes, ureas, ethers, carbonates, or thioesters, or corresponding substituted amides.
  • Some invention embodiments specifically exclude Ll and L2 from being any one or any combination of the moieties listed above in Structure Table II, above.
  • invention embodiments comprise linear polymers, some exclusively so. But various invention embodiments can contain polymers that are branched or cross-linked, partially cross-linked, or not cross-linked, as desired. In some embodiments, invention polymers have less than 0.1 mole percent of branched polymers in which the branches have more than 10 atoms; alternatively, invention polymers have less than 0.01 mole percent of such branched polymers; alternatively, invention polymers have legs than 0.001 mole percent of such branched polymers.
  • invention polymers have greater than 0.1 mole percent of branched polymers in which the branches have more than 10 atoms; alternatively, invention polymers have greater than 0.01 mole percent of such branched polymers; alternatively, invention polymers have greater than 0.001 mole percent of such branched polymers. In some embodiments, invention polymers have less than 0.1 mole percent of cross-linked polymers; alternatively, invention polymers have less than 0.01 mole percent of cross-linked polymers; alternatively, invention polymers have less than 0.001 mole percent of cross-linked polymers.
  • invention polymers have greater than 0.1 mole percent of cross-linked polymers; alternatively, invention polymers have greater than 0.01 mole percent of cross-linked polymers; alternatively, invention polymers have greater than 0.001 mole percent of cross-linked polymers.
  • Partially cross-linked means having greater than 0.001 mole percent and less than 0.1 mole percent of cross-linked polymers.
  • cross-linking occurs through functional groups pendant from the polymer backbone.
  • urethanes or amides in the backbone can serve as the cross-linking site, via the use of diisocyanates.
  • Those of ordinary skill in the art will recognize that other ways of achieving cross-links between polymer chains function with invention copolymers.
  • some embodiments may have UV polymerizable groups in the monomers. Such groups are typically acrylates or methacrylates.
  • One general scheme would include placing acrylate or methacrylate groups onto the phenyl groups after the condensation polymerization.
  • the acrylate or methacrylate groups would be present on the PEG based-diamine, aliphatic diamine, or the dif nctional phenyl moiety (e.g., terephthalic acid).
  • This scheme is workable if the condensation reactions are selective enough not to react with the acrylate or methacrylate groups. This gives rise to another class of polymers.
  • Some embodiments comprise invention polymers coated onto a medical device containing or constructed from a polymer, a medical device containing or constructed from a metal, or a bare medical device, or invention polymers coated on top of a drug coating already present on a medical device.
  • some embodiments comprise invention polymers disposed between a medical device and a drug coating.
  • some embodiments comprise invention polymers composing polymer-based medical " devices or invention polymers composing medical device substrates (implantable or not).
  • Some invention embodiments comprise medical devices not made from polymer-containing or -constructed stents.
  • Some invention embodiments comprise stents not made from metal-containing or. constructed stents.
  • invention polymers serve as the base material for coatings on medical devices.
  • coatings may contain a primer layer composed of an invention polymer or composed of a type-two polymer, as described below. Some embodiments exclude a primer layer.
  • invention polymers add conventional drugs ' , such as small, hydrophobic drugs, to invention polymers (as discussed in any of the embodiments, above), making them biostable, drug systems.
  • invention polymers can be coated as blends with a variety of biobeneficial polymers. Moreover, they can serve as base or topcoat layers for biobeneficial polymer layers.
  • the selected drug can inhibit vascular, smooth muscle cell activity. More specifically, the drug activity can aim at inhibiting abnormal or inappropriate migration or proliferation of smooth muscle cells to prevent, inhibit, reduce, or treat restenosis.
  • the drug can also include any substance capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. Examples of such active agents include antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, and antioxidant substances as well as their combinations.
  • An example of an antiproliferative substance is actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, WI 53233; or COSMEGEN available from Merck).
  • actinomycin D Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin Ii, actinomycin Xi, and actinomycin C ⁇ .
  • antineoplastics include paclitaxel and docetaxel.
  • antiplatelets examples include aspirin, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prosfacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor-antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E-3B® (an antiplatelet drug from Centocor).
  • aspirin sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prosfacyclin analogs
  • dextran D-phe-pro-arg-chloromethylketone
  • D-phe-pro-arg-chloromethylketone synthetic antithrombin
  • dipyridamole
  • antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mutamycin.
  • cytostatic or antiproliferative agents include angiopeptin (a somatostatin analog from Ibsen), angiotensin converting enzyme inhibitors such as CAPTOPRIL (available from Squibb), CILAZAPRIL (available from Hoffman-LaRoche), or LISINOPRIL (available from Merck & Co., Whitehouse Station, NJ), calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, histamine antagonist, LOVASTATIN (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck &Co.), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available from Glazo), Seramin
  • a PDGF antagonist triazolopyrimidine
  • Other useful drugs may include alpha-interferon, genetically engineered epithelial cells, dexamethasone, estradiol, clobetasol propionate, cisplatin, insulin sensitizers, receptor tyrosine kinase inhibitors, and carboplatin. Exposure of the composition to the drug should not adversely alter the drug's composition or characteristic. Accordingly, drug-containing embodiments choose drugs that are compatible with the blended composition. • Rapamycin is a suitable drug. Additionally, 40-O-(2-hydroxy)ethyl-rapamycin, or a functional analog or structural derivative thereof, is suitable, as well.
  • Examples of analogs or derivatives of 40-O-(2-hydroxy)ethyl-rapamycin include, among others, 40-O-(3-hydroxy)propyl-rapamycin and 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin.
  • Those of ordinary skill in the art know of various methods and coatings for advantageously controlling the release rate of drugs, such as 40-O-(2-hydroxy)ethyl-rapamycin.
  • Some embodiments choose the drug such that it does not contain at least one of or any combination of antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, or antioxidant substances.
  • Some invention embodiments choose the drug such that it does not contain at least one of or any combination of actinomycin D, derivatives and analogs of Actinomycin D, dactinomycin, actinomycin IV, actinomycin L, actinomycin X[, actinomycin Ci, paclitaxel, docetaxel, aspirin, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin, prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist, reco binant hirudin, thrombin inhibitor and 7E-3B, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, mutamycin, angiopeptin, an
  • Some invention embodiments comprise a drug or drug combination, and some require a drug or combination of drugs. Of the drugs specifically listed above, some invention embodiments exclude a single or any combination of these drugs.
  • blends could also be formulated to modulate or tune the release rate of drugs from coatings, reservoirs, or particles composed of these blends and drugs or therapeutic agents.
  • Blends with other polymers can be formulated to modulate the mechanical properties of invention polymers. Therefore, some invention embodiments comprise polymer blends with other polymeric components. For purposes of this disclosure, these other polymeric components are sometimes referred to as type-two polymers. For instance, type-two polymers could be blended into invention polymers to modify mechanical or biological properties or vice versa.
  • Type-two polymers include, among others, polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D,L-la ' ctide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(tyrosine derived carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly(anhydrides), poly(orthoesters), and poly(ester amides) or combinations of these polymers.
  • polymer blends with invention polymers do not contain at least one of polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D J L-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(hydroxybutyrate-co-hydroxyvalerate), poly(tyrosine derived carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly( anhydrides), poly(orthoesters), or poly(ester amides).
  • polycaprolactone poly(D,L-lactide), poly(L-lactide), poly(D J L-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-
  • Type-two polymers also include ethylene vinyl alcohol copolymer, poly (hydro xyvalerate); poly(L-iactic acid); polycaprolactone; poly(lactide-co-glycolide); polyfhydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanl ydride; po!y(gIycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g.
  • PEO/PLA polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; ; poly(ester-urethanes); poly(ether-urethanes); poly(urea- urethanes); poly(silicone-urethanes); polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers- and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; poly(vinylidene fluoride-co-hexafluoropropene), poly(vinylidene fluoride-co- chloro
  • Some invention embodiments comprise, and some invention embodiments require, a type-two polymer used along with invention polymers. Some invention embodiments comprise and some invention embodiments require combining at least two type-two polymers with invention polymers. Of the . type-two polymers disclosed above, some invention embodiments exclude a single or any combination of type-two polymers.
  • invention polymers are used with type-two polymers
  • the invention polymers are mixed or blended with the type-two polymers.
  • some embodiments comprise invention polymers physically blended with PEG, POLYACTIVE, or other biobeneficial polymers. Additionally, some embodiments employ invention polymers blended with biobeneficial polymers and type-two polymers.
  • modulate biological outcome means adjusting the polymer biobeneficial-component content in order to minimize fibrinogen absorption, platelet, binding, the number of adherent macrophages and inflammatory cells, and the degree of inflammatory cell activation.
  • Some embodiments comprise invention polymers combined with other polymers in multilayer arrangements.
  • an invention polymer could under- or over-lay another polymer such as a polymer coated on a device, a medical device, an implantable medical device, or a stent.
  • the invention polymer can be used neat in this regard, or it can first B mixed with a ' separate invention polymer or a type-two polymer before layering.
  • invention polymers do not underlay another polymer; in other embodiments, invention polymers must overlay another polymer.
  • implantable devices useful in the present invention include self- expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular assist devices, artificial hearts, cardiopulmonary by-pass circuits, blood oxygenators, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA).
  • the underlying structure of the device can be of virtually any design.
  • the device can comprise a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
  • ELGILOY cobalt chromium alloy
  • 316L stainless steel
  • high nitrogen stainless steel e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
  • BIODUR 108 cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium
  • MP35N consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
  • MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
  • Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.
  • Some invention embodiments define the genre of medical devices to exclude at least one of self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular assist devices, artificial hearts, cardiopulmonary by-pass circuits, blood oxygenators; or endocardial leads.
  • grafts e.g., aortic grafts
  • vascular grafts e.g., vascular grafts
  • pacemaker electrodes e.g., guidewires, ventricular assist devices, artificial hearts, cardiopulmonary by-pass circuits, blood oxygenators; or endocardial leads.
  • a coating for an implantable medical device such as a stent, according to embodiments of the present invention, can be a multi-layer structure that can include the following three layers:
  • a drug-polymer layer also referred to as “reservoir”, or “reservoir layer” or alternatively a polymer-free drug layer;
  • Some invention embodiments comprise multilayered structures in which an invention polymer is present in one or more of the layers of the multilayered structure.
  • each medical device coating layer comprises dissolving the polymer or a polymer blend in a solvent or a solvent mixture, and applying the solution onto the medical device (such as by spraying the medical device with the solution or by dipping the medical device into the solution). After applying the solution onto the medical device, the coating dries by solvent evaporation. Drying at elevated temperatures accelerates the process.
  • Combining the drug with the polymer solution, as described above, provides for incorporating the drug into the reservoir layer.
  • dissolving the drug in a suitable solvent or solvent mixture an applying the drug solution to the medical device provides for a substantially polymer-free drug layer.
  • the drug can be introduced as a colloid, such as a suspension in a solvent.
  • Dispersing the drug in the solvent uses conventional techniques. Depending on a variety of factors, e.g., the nature of the drug, those having ordinary skill in the art can select the solvent for the suspension, as well as the quantity of the dispersed -drug. ' Some embodiments mix these suspensions with a polymer solution and apply the mixture onto the device, as described above. Alternatively, some embodiments apply the drug suspension to the device without mixing it with the polymer solution.
  • the drug-polymer layer can be applied directly onto at least a part of the medical device surface to serve as a reservoir for at least one active agent or. a drug.
  • the optional primer layer can be applied between the device and the reservoir to improve polymer adhesion to the medical device.
  • Some embodiments apply the topcoat layer over at least a portion of the reservoir layer, and the topcoat layer serves as a rate limiting membrane, which helps to control the rate of release of the drug.
  • Some drug releasing processes include at least two steps. First, the topcoat polymer absorbs the drug at the drug-polymer-topcoat interface. Next, the drug diffuses through the topcoat using empty spaces between the polymer molecules as diffusion pathways. Next, the drug arrives to the outer surface of the topcoat, and desorbs into the blood stream.
  • Invention polymers can be prepared by polycondensation reactions. First, the amine- terminated PEG is combined with terephthaloyl chloride with added pyridine to absorb the released HC1. After this block has reacted, the aliphatic diamine is added with additional teraphthaloyl chloride. Irganox 1330 can be added as an antioxidant to protect the PEG, as it is used in the synthesis of POLYACTIVE. Routes that use dimethyl terephthalate would avoid using the acid chloride. Application of heat and vacuum to remove the generated methanol will drive the polymerization. [0058] Of course, modifications to this synthesis must be made when Ll or L2 are not prepared to contain amide linkages, i.e. when Ll and L2 do not have the structure shown below. Such modifications are well within the skill level of one of ordinary skill in the art.
  • Terephthaloyl chloride (47.51 g, 0.234 moles) is slowly added to the reaction vessel and the solution slowly heated to 60 °C and allowed to react for 4 hours. After cooling, slow addition of the reaction mixture into 2 liters of stirred, deionized water will cause precipitation of the polymer, the formula of which is shown below in Formula XVII.
  • Formulas Formula XIX-Formula XXII represent the same polymer, the only difference in the orientations of the benzoyl-derived group.
  • listing one of formulas Formula XLX-Formula XXII represents each of Formula XIX-Formula XXII.

Abstract

This disclosure covers polymers, some of which are useful in medical device applications. The polymers comprise at least two different blocks, at least one L1 block with the formula (I); and at least one L2 block with the formula (II). Medical devices comprising these polymers, mixtures of these polymers with therapeutic agents, and methods of making these polymers and mixtures are within the scope of this disclosure. Some of these medical devices are implantable within a mammalian body, such as in a body lumen.

Description

Biobeneficial Polyamide/Polyethylene glycol Polymers for Use with Drug Eluting Stents
BACKGROUND
[0001] ' Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A surgeon introduces a catheter assembly having a balloon portion percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The surgeon advances the catheter assembly through the coronary vasculature until the balloon portion crosses the occlusive lesion. Once in position, the surgeon inflates the balloon to radially compress the atherosclerotic plaque of the lesion and remodel the vessel wall. The surgeon then deflates the balloon to remove the catheter.
[0002] But this procedure can create intimal flaps or tear arterial linings, which can collapse and occlude the vessel after balloon removal. Moreover, thrombosis and restenosis of the artery may develop over several months following the procedure, which may require another angioplasty procedure or a by-pass operation. To reduce artery occlusion, thrombosis, and restenosis, the surgeon can implant a stent into the vessel.
[0003] Stents are used not only mechanically, but also to provide biological therapy. Mechanically, stents act as scaffoldings, physically holding open and, if desired, expanding the vessel wall. Typically, stents compress for insertion through small vessels and then expand to a larger diameter once in position. U. S. Patent No. 4,733,665, issued to Palmaz; U. S. Patent No. 4,800,882, issued to Gianturco; and U. S. Patent No. 4,886,062, issued to ' Wiktor disclose examples of PTCA stents. [0004] Medicating the stent provides for pharmacological therapy. Medicated stents allow local drug administration at the diseased site. To provide an effective drug concentration at the treated site, systemic treatment often requires concentrations that produce adverse or toxic effects. Local delivery advantageously allows for smaller systemic drug levels in comparison to systemic treatment. Because of this, local delivery produces fewer side effects and achieves more favorable results. One proposed method for medicating stents involves coating a polymeric carrier onto a stent surface. This method applies a solution that includes a solvent, a dissolved polymer, and a dissolved or dispersed drug to the stent. As the solvent evaporates, it leaves a drug impregnated, polymer coating on the stent.
[0005] Current biomaterials research aims at controlling protein adsorption on implantable medical devices. Current biomaterials exhibit uncontrolled protein adsorption, leading to a mixed layer of partially denatured proteins. Current surfaces contain different cell binding sites resulting from adsorbed proteins such as fibrinogen and immunoglobulin G. Platelets and inflammatory cells such as macrophages and neutrophils adhere to these surfaces. When so activated, these cells secret a wide variety of pro-inflammatory and proliferative factors. Non- fouling surfaces control these events. Thus surfaces absorb little or no protein, primarily due to their hydrophilicity. One prior art approach creates these surfaces by using hyaluronic acid and polyethylene glycol. Non-fouling surfaces or coatings are a subset of biobeneficial coatings. Biobeneficial coatings benefit the treatment site without releasing pharmaceutically or therapeutically active agents, ("drug(s)"). Another type of biobeneficial coating contains free- radical scavengers, which preserve nitric oxide and prevent oxidative damage.
SUMMARY
[0006] This invention relates to biobeneficial copolymers, some of which are useful in medical device applications. Some of these medical devices are implantable within a mammalian body, such as in a body lumen or blood vessel. For purposes of this disclosure, the term "biobeneficial" is a description for any surface that bestows biological benefit to an implantable medical device without releasing drug(s). The copolymers comprise at least two different blocks, at least one l block with the formula shown in Formula I, below
Figure imgf000004_0001
Formula I and at least one L2 block with the formula srϊown in Formula II, below
Figure imgf000004_0002
Formula II [0007] More generally, the Ll block can be as shown in Formula III, below.
Figure imgf000004_0003
Formula III
[0008] The Ll blocks are the same or different. R are the same or different for each occurrence and are 1-16 carbon (un)substituted, (un)branched alkyl or (un)substituted, (un)branched diol or triol oligomers. And k are the same or different 'for each Ll block ranging from 6 to 460. Similarly, the L2 blocks are the same or different, and j are the same or different for each L2 block ranging from 2 to 30. Some embodiments select R to be the same; some embodiments select Rs to be different. Exemplary R include oligomers of ethylene glycol, propylene glycol (1,2- and 1,3 -substituted isomers), tetramethylene glycol (1,2-, 1,3-, 1,4-, and 2,3-substituted isomers), and hexamethylene glycol (1,2-, 1,3-, 1,4- 1,5-, 1,6-, 2,3-, 2,4-, 2,5-, 3,4-substituted isomers). One of ordinary skill in the art recognizes that any of the preceding glycols will yield unbranched moieties when substituted at the first and last carbon atom and will yield branched moieties with other substitutions patterns. Some embodiments are envisioned that use mixtures of polyols. In addition to polyol oligomers, R can be (un)branched alkyl, alkenyl, or alkynyl moieties. In many instances throughout the disclosure the R-group is- specified as an ethylene or ethylene glycol unit. When this occurs, the formula is intended to represent its genus with an R-groups as defined in this paragraph and is intended to represent the species with the specified R-group shown. Also, as a point of clarity, the above Ll block is written below in Formula IV with R defined as it would be if the polyether portion of the Ll block were selected to be PEG and the Ll portion is a- diamide.
Figure imgf000005_0001
Formula IV
[0009] Ll and L2, independently, represent linkages with the formula shown in Formula V, above.
Figure imgf000005_0002
Formula V [0010] In this formula, Y and Z are independently selected from the moieties shown in Structure Table I, below.
Structure Table I
0 0 H +— c-o— ester -0 — c ll — N l — urethane 0 H II 1 -0 — ether amide
H 0 0 • urethane -0 — c — 0 — carbonate H 0 H 0 1 II 1 • — C — — - urea -c — s — thioester
Formula VI 0 II provided that if Y and Z are the same, they are not • c ° . In the above list, the heavy circle indicates the position at which Y or Z attaches to the phenyl ring of Ll or L2, respectively.
[0011] In some embodiments, these polymers compose structural polymeric medical devices and compose coatings for polymeric, metallic, ceramic, glass, or composite medical devices. In addition to this, these polymers can be mixed with other polymers, with drugs, or with both. Methods of making medical devices using these polymers are disclosed, as well.
DETAILED DESCRIPTION
[0012] This disclosure reveals a family of biobeneficial, polyamide-polyethylene-glycol polymers. In some embodiments, these polymers compose the base material for implantable medical devices. In some embodiments, implantable medical devices comprise these polymers. And in some embodiments, these polymers compose implantable medical device coatings. This polymer family comprises the reaction products of various reactants, wherein reactants comprise the following basic components: terephthalic acid (Formula VII, below) or a similar 1,4- difunctionally substituted benzyl group, amine-terminated polyethylene glycol or another group, as described below, and at least one aliphatic diamine. Throughout this disclosure, 1,4- disubstituted phenyl or benzyl rings axe referred to or depicted. For this disclosure, such reference or depiction includes variations in which the phenyl or benzyl rings are additionally substituted at least at the 2, 3, 5, or 6 positions. Any substitution is allowed.
Figure imgf000007_0001
Formula VII
[0013] Invention embodiments contain amine-terminated polyethylene glycol, such as the ED series of Jeffamine polymers (from Huntsman Chemical) or mono-amine-terminated PEG (from Shearwater Polymers). These Jeffamine polymers have a polyethylene glycol backbone with some polypropylene glycol units at the chain ends. The polypropylene units contain the primary amine.
[0014] Invention embodiments contain an aliphatic diamine, such as 1,2-ethanediamine (Formula VIII, below),
H,N- -CH2 -NH7 or Formula VIII
1,4-butanediamine (Formula IX, below),
H,N- CH, -NH2
Formula IX [0015] Both of these diamines are biocompatible in the unlikely event that in-vivo use causes their release. The synthesis of invention polymers is straightforward using standard nylon polymerization techniques. Other useful diamines are 1,5-pentanediamine, 1,6-heaxanediamine, and 1 ,6-diaminocyclohexane. Embodiments that have branching from the diamine backbone are . within the scope of this description. In some embodiments, the diamine is selected from straight chain or branched, aliphatic diamino compounds where the amino groups are primary or secondary and the total number of carbons per diamine is 16 or less.
H2N PEG R PEG NH2
Formula X [0016] In Formula X, R can be polyethylene, polypropylene, polyisobutylene, polyisόprene, polybutene, poly(hexamethylene glycol), poly(tetramethylene glycol), or poly(propylene glycol), and R has a molecular weight of 26 to 500 Daltons. Some embodiments can be described as having an optional linkage between the R and the PEG. This linkage could be any of those shown in Structure Table I, above.
[0017] Some invention embodiments select the amine-terminated polyethylene glycol, or the aliphatic diamines, or both, to be primary amines. One of ordinary skill in the art recognizes that similar chemistry would arise from using secondary amines for the amine-terminated polyethylene glycol or the aliphatic diamines. This disclosure defines a linkage prepared using secondary amines as a "substituted amide linkage" shown in Formula XI, below:
Figure imgf000008_0001
Formula XI
[0018] Some invention embodiments select the amine-terminated polyethylene glycol or the aliphatic diamines or both to be secondary amines. On the other hand, some invention embodiments specifically exclude secondary amines from being the amine-terminated polyethylene glycol or the aliphatic diamines or both. Likewise, some invention embodiments exclude primary amines from- being the amine-terminated polyethylene glycol or the aliphatic diamines or both.
[0019] For polymers that contain bioabsorbable components, the biobeneficial component should also be bioabsorbable. Similarly, for polymers containing biostable components, such as EVAL, the biobeneficial component would ideally be biostable, as well. This is because the biobeneficial feature has both acute and chronic, long-term effects. PEG, for example, works by resisting protein adhesion and denaturation at the implant surface.
[0020] This disclosure reveals, among other embodiments, a biostable version of a polyester, biodegradable eopolyiher POLYACTIVE in which at least some replacement of the ester linkages by amide (or other) linkages occurs. POLYACTIVE is a trade name of a PBT-PEG ' group of products and is available from IsoTisCorp. of.Holland. In various brands of POLYACTIVE, the molar ratio between the units derived from ethylene glycol and the units derived from butylene terephthalate falls between about 0.01 :1 and about 1:1. The molecular weight of the units derived from ethylene glycol can be between about 300 and about 10,000 Daltons. The structure of POLYACTIVE is shown in Formula.XII, below.
Figure imgf000009_0001
Formula XII
[0021] For POLYACTIVE, k ranges from 4 to 230, or more narrowly, from 7 to 91. The values of 1, m, and n constrain each other for a given molecular weight. LTherefore, the value of m is set to unity and the values of 1 and n will give the ratio of the two blocks and the total molecular weight. 1 ranges from 0.003 to 0.60, or more narrowly, from 0.01 to 0.45. And n ranges from 30 to 500, or more narrowly, from 100 to 375.
[0022] Replacing ester linkages with amide linkages yields Formula XIII, below:
Figure imgf000010_0001
Formula XIII [0023] For invention polymers, k ranges from 4 to 230, or more narrowly, from 7 to 91. 1 ranges from 0.005 to 2.0, or more narrowly, from 0.01 to 1.6. m is set at unity. And n ranges from 20 to 600, or more narrowly, from 40 to 450.
[0024] In some embodiments, amide linkages replace all ester linkages in POLYACTIVE. Alternatively, in some embodiments, amide linkages replace 25-100 percent of the ester linkages; amide linkages replace 50-100 percent of the ester linkage; amide linkages replace 75- 100 percent of the ester linkages; amide linkages replace 95-100 percent of the ester linkages; or amide linkages replace 99-100 percent of the ester linkages. Alternatively, in some embodiments 25-100 percent of the ester linkages remain after some amide linkage replacement; 50-100 percent of the ester linkage remain after some amide linkage replacement; 75 -100- percent of the ester linkages remain after some amide linkage replacement; 95-100 percent of the ester linkages remain after some amide linkage replacement; or 99-100 percent of the ester linkages remain after some amide linkage replacement.
[0025] This amide substitution removes the ester linkage from POLYACTIVE or reduces the number of ester linkages compared with the number in POLYACTIVE. Ester linkages hydrolyze in-vivo. But amide linkages are many times more stable. Some invention embodiments select the polymer formulation such that the resulting polymer is substantially broken down by the in vivo environment in an amount of time of from 1 to 24 months; alternatively, in an amount of time of from 2 to 18 months; alternatively, in an amount of time of from 3 to 12 months. For purposes of this disclosure, substantially broken down means that non- invasive diagnostic procedures as skilled artisans normally employ cannot detect the polymer in vivo.
[0026] For some embodiments, biocompatible means that the material passes or is found acceptable by at least one of the following in vitro tests, as specified by ISO 10993. These in vitro tests would include ISO 10993-5 cytotoxicity (this is a L929 mouse fibroblast test using extracts of the material); ISO 10993-4 hemocompatibility (this is a specific test for thrombosis, coagulation, platelet consumption, hematology, and immunology); ISO 10993-3 genotoxicity (this includes the Ames test, mouse cell lymphoma test, and Chinese hamster ovary cell test).
[0027] In some embodiments, invention polymers comprise at least one Ll block, shown in Formula III, above and at least one L2 block, shown in Formula II, above. In these invention polymers, the Ll blocks are the same or different and k are the same or different for each Ll block and range from 6 to 460. Likewise, the L2 blocks are the same or different and j are the same or different for each L2 block and range from 2 to 30.
[0028] Formula XIV and Formula XV, below, represent some invention embodiments.
Figure imgf000011_0001
Formula XIV
R— f— 0-C2H4-j— O-R— L1 -CH, -L2- m n
Formula XV
[0029] For these embodiment, k, 1, m, n, take the above-disclosed values, m equals one, leaving 1 to define the ratio of 1 to m and n to define to total molecular weight, j ranges from 2 to 30, or more narrowly, from 2 to 6.
[0030] Ll and L2 independently have Formula V, as shown above. Some embodiments independently select Ll and L2, as indicated above. In other embodiments, Ll and L2 are purposely chosen to be the same. Other embodiments purposely choose Ll and L2 to be different from each other. In any of these embodiments, appropriate selection of Y and Z yields Y and Z that are both more resistant to in vivo hydrolysis than an ester moiety, appropriate selection of Y and Z yields Y and Z in which one or the other is more resistant to in vivo hydrolysis than an ester moiety, or appropriate selection of Y and Z yields Y and Z that are both less resistant to in vivo hydrolysis than an ester moiety. One of ordinary skill in the art recognizes that if a secondary amine were chosen above, any amides selected for Y or Z would be substituted amides. Some invention embodiments specifically exclude Y or Z equal to one of or any combination of esters, amides, urethanes, ureas, ethers, carbonates, or thioesters, or corresponding substituted amides.
[0031] Structure Table II, below, shows non-inclusive examples of Ll and L2:
Structure Table II
Figure imgf000012_0001
[0032] Some invention embodiments specifically exclude Ll and L2 from being any one or any combination of the moieties listed above in Structure Table II, above.
[0033] Some invention embodiments comprise linear polymers, some exclusively so. But various invention embodiments can contain polymers that are branched or cross-linked, partially cross-linked, or not cross-linked, as desired. In some embodiments, invention polymers have less than 0.1 mole percent of branched polymers in which the branches have more than 10 atoms; alternatively, invention polymers have less than 0.01 mole percent of such branched polymers; alternatively, invention polymers have legs than 0.001 mole percent of such branched polymers. In some embodiments, invention polymers have greater than 0.1 mole percent of branched polymers in which the branches have more than 10 atoms; alternatively, invention polymers have greater than 0.01 mole percent of such branched polymers; alternatively, invention polymers have greater than 0.001 mole percent of such branched polymers. In some embodiments, invention polymers have less than 0.1 mole percent of cross-linked polymers; alternatively, invention polymers have less than 0.01 mole percent of cross-linked polymers; alternatively, invention polymers have less than 0.001 mole percent of cross-linked polymers. In some embodiments, invention polymers have greater than 0.1 mole percent of cross-linked polymers; alternatively, invention polymers have greater than 0.01 mole percent of cross-linked polymers; alternatively, invention polymers have greater than 0.001 mole percent of cross-linked polymers. Partially cross-linked means having greater than 0.001 mole percent and less than 0.1 mole percent of cross-linked polymers.
[0034] In some instances, cross-linking occurs through functional groups pendant from the polymer backbone. For instance, in some embodiments urethanes or amides in the backbone can serve as the cross-linking site, via the use of diisocyanates. Those of ordinary skill in the art will recognize that other ways of achieving cross-links between polymer chains function with invention copolymers. For example, to UV crosslink the polymers, some embodiments may have UV polymerizable groups in the monomers. Such groups are typically acrylates or methacrylates. One general scheme would include placing acrylate or methacrylate groups onto the phenyl groups after the condensation polymerization. In another scheme, the acrylate or methacrylate groups would be present on the PEG based-diamine, aliphatic diamine, or the dif nctional phenyl moiety (e.g., terephthalic acid). This scheme is workable if the condensation reactions are selective enough not to react with the acrylate or methacrylate groups. This gives rise to another class of polymers.
[0035] Some embodiments comprise invention polymers coated onto a medical device containing or constructed from a polymer, a medical device containing or constructed from a metal, or a bare medical device, or invention polymers coated on top of a drug coating already present on a medical device. Alternatively, some embodiments comprise invention polymers disposed between a medical device and a drug coating. Also, some embodiments comprise invention polymers composing polymer-based medical "devices or invention polymers composing medical device substrates (implantable or not). Some invention embodiments comprise medical devices not made from polymer-containing or -constructed stents. Some invention embodiments comprise stents not made from metal-containing or. constructed stents.
[0036] In some embodiments, invention polymers serve as the base material for coatings on medical devices. In some embodiments, coatings may contain a primer layer composed of an invention polymer or composed of a type-two polymer, as described below. Some embodiments exclude a primer layer.
[0037] Some embodiments add conventional drugs', such as small, hydrophobic drugs, to invention polymers (as discussed in any of the embodiments, above), making them biostable, drug systems. Some embodiments graft on conventional drugs or mix conventional drugs with invention polymers. Invention polymers can be coated as blends with a variety of biobeneficial polymers. Moreover, they can serve as base or topcoat layers for biobeneficial polymer layers.
[0038] The selected drug can inhibit vascular, smooth muscle cell activity. More specifically, the drug activity can aim at inhibiting abnormal or inappropriate migration or proliferation of smooth muscle cells to prevent, inhibit, reduce, or treat restenosis. The drug can also include any substance capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. Examples of such active agents include antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, and antioxidant substances as well as their combinations. An example of an antiproliferative substance is actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue, Milwaukee, WI 53233; or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin Ii, actinomycin Xi, and actinomycin C\. Examples of antineoplastics include paclitaxel and docetaxel. Examples of antiplatelets, anticoagulants, antifibrins, and antithrombins include aspirin, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prosfacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor-antagonist, recombinant hirudin, thrombin inhibitor (available from Biogen), and 7E-3B® (an antiplatelet drug from Centocor). Examples of antimitotic agents include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, and mutamycin. Examples of cytostatic or antiproliferative agents include angiopeptin (a somatostatin analog from Ibsen), angiotensin converting enzyme inhibitors such as CAPTOPRIL (available from Squibb), CILAZAPRIL (available from Hoffman-LaRoche), or LISINOPRIL (available from Merck & Co., Whitehouse Station, NJ), calcium channel blockers (such as Nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, histamine antagonist, LOVASTATIN (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug from Merck &Co.), monoclonal antibodies (such as PDGF receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor (available from Glazo), Seramin (a P.DGF antagonist), serotonin blockers, thioprotease. inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. Other useful drugs may include alpha-interferon, genetically engineered epithelial cells, dexamethasone, estradiol, clobetasol propionate, cisplatin, insulin sensitizers, receptor tyrosine kinase inhibitors, and carboplatin. Exposure of the composition to the drug should not adversely alter the drug's composition or characteristic. Accordingly, drug-containing embodiments choose drugs that are compatible with the blended composition. • Rapamycin is a suitable drug. Additionally, 40-O-(2-hydroxy)ethyl-rapamycin, or a functional analog or structural derivative thereof, is suitable, as well. Examples of analogs or derivatives of 40-O-(2-hydroxy)ethyl-rapamycin include, among others, 40-O-(3-hydroxy)propyl-rapamycin and 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin. Those of ordinary skill in the art know of various methods and coatings for advantageously controlling the release rate of drugs, such as 40-O-(2-hydroxy)ethyl-rapamycin.
[0039] Some embodiments choose the drug such that it does not contain at least one of or any combination of antiproliferative, antineoplastic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, or antioxidant substances. Some invention embodiments choose the drug such that it does not contain at least one of or any combination of actinomycin D, derivatives and analogs of Actinomycin D, dactinomycin, actinomycin IV, actinomycin L, actinomycin X[, actinomycin Ci, paclitaxel, docetaxel, aspirin, sodium heparin, low molecular weight heparin, hirudin, argatroban, forskolin, vapiprost, prostacyclin, prostacyclin analogs, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist, reco binant hirudin, thrombin inhibitor and 7E-3B, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, adriamycin, mutamycin, angiopeptin, angiotensin converting enzyme inhibitors, CAPTOPRIL, CILAZAPRIL, or LISINOPRIL, calcium channel blockers, Nifedipine, colchicine, fibroblast growth factor (FGF) antagonists, histamine antagonist, LOVASTATIN, monoclonal antibodies, PDGF receptors, nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitor, Seramin, PDGF antagonists, serotonin blockers, thioprotease inhibitors, triazolopyrimidine, nitric oxide, alpha-interferon, genetically engineered epithelial cells, dexamethasone, estradiol, clobetasol propionate, cisplatin, insulin sensitizers, receptor tyrosine kinase inhibitors, carboplatin, Rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin, or a functional analogs of 40-O-(2- hydroxy)ethyl-rapamycin, structural derivative of 40-O-(2-hydroxy)ethyl-rapamycin, 40-O-(3-. hydroxy)propyl-rapamycin, and 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin.
[0040] Some invention embodiments comprise a drug or drug combination, and some require a drug or combination of drugs. Of the drugs specifically listed above, some invention embodiments exclude a single or any combination of these drugs.
[0041] These blends could also be formulated to modulate or tune the release rate of drugs from coatings, reservoirs, or particles composed of these blends and drugs or therapeutic agents. Blends with other polymers can be formulated to modulate the mechanical properties of invention polymers. Therefore, some invention embodiments comprise polymer blends with other polymeric components. For purposes of this disclosure, these other polymeric components are sometimes referred to as type-two polymers. For instance, type-two polymers could be blended into invention polymers to modify mechanical or biological properties or vice versa. Type-two polymers include, among others, polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D,L-la'ctide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(tyrosine derived carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly(anhydrides), poly(orthoesters), and poly(ester amides) or combinations of these polymers. In some embodiments, polymer blends with invention polymers do not contain at least one of polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(DJL-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(hydroxybutyrate-co-hydroxyvalerate), poly(tyrosine derived carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly( anhydrides), poly(orthoesters), or poly(ester amides).
[0042] Type-two polymers also include ethylene vinyl alcohol copolymer, poly (hydro xyvalerate); poly(L-iactic acid); polycaprolactone; poly(lactide-co-glycolide); polyfhydroxybutyrate); poly(hydroxybutyrate-co-valerate); polydioxanone; polyorthoester; polyanl ydride; po!y(gIycolic acid); poly(D,L-lactic acid); poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); cyanoacrylates; poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g. PEO/PLA); polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; ; poly(ester-urethanes); poly(ether-urethanes); poly(urea- urethanes); poly(silicone-urethanes); polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers- and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; poly(vinylidene fluoride-co-hexafluoropropene), poly(vinylidene fluoride-co- chlorotrifluoropropene); polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins; polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins; polyurethanes; rayon; rayon-triacetate; cellulose; cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose.
[0043] Some invention embodiments comprise, and some invention embodiments require, a type-two polymer used along with invention polymers. Some invention embodiments comprise and some invention embodiments require combining at least two type-two polymers with invention polymers. Of the .type-two polymers disclosed above, some invention embodiments exclude a single or any combination of type-two polymers.
[0044] In some embodiments in which invention polymers are used with type-two polymers, the invention polymers are mixed or blended with the type-two polymers.
[0045] For example, some embodiments comprise invention polymers physically blended with PEG, POLYACTIVE, or other biobeneficial polymers. Additionally, some embodiments employ invention polymers blended with biobeneficial polymers and type-two polymers.
[0046] For purposes of this disclosure, "modulate biological outcome" means adjusting the polymer biobeneficial-component content in order to minimize fibrinogen absorption, platelet, binding, the number of adherent macrophages and inflammatory cells, and the degree of inflammatory cell activation.
[0047] Some embodiments comprise invention polymers combined with other polymers in multilayer arrangements. For example, an invention polymer could under- or over-lay another polymer such as a polymer coated on a device, a medical device, an implantable medical device, or a stent. The invention polymer can be used neat in this regard, or it can first B mixed with a' separate invention polymer or a type-two polymer before layering. In some embodiments, invention polymers do not underlay another polymer; in other embodiments, invention polymers must overlay another polymer.
[0048] Examples of implantable devices useful in the present invention include self- expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular assist devices, artificial hearts, cardiopulmonary by-pass circuits, blood oxygenators, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA). The underlying structure of the device can be of virtually any design. The device can comprise a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N," "MP20N," ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. "MP35N" and "MP20N" are trade names for alloys of cobalt, nickel, chromium, and molybdenum available ' from Standard Press Steel Co., Jenkintown, PA. "MP35N" consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. "MP20N" consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.
[0049] Some invention embodiments define the genre of medical devices to exclude at least one of self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular assist devices, artificial hearts, cardiopulmonary by-pass circuits, blood oxygenators; or endocardial leads.
[0050] A coating for an implantable medical device, such as a stent, according to embodiments of the present invention, can be a multi-layer structure that can include the following three layers:
(a) an optional primer layer;
(b) a drug-polymer layer (also referred to as "reservoir", or "reservoir layer") or alternatively a polymer-free drug layer; and/or
(c) an optional, topcoat layer, which is likewise drug-containing or drug-free.
[0051] Some invention embodiments comprise multilayered structures in which an invention polymer is present in one or more of the layers of the multilayered structure.
[0052] In some embodiments, forming each medical device coating layer comprises dissolving the polymer or a polymer blend in a solvent or a solvent mixture, and applying the solution onto the medical device (such as by spraying the medical device with the solution or by dipping the medical device into the solution). After applying the solution onto the medical device, the coating dries by solvent evaporation. Drying at elevated temperatures accelerates the process.
[0053] Combining the drug with the polymer solution, as described above, provides for incorporating the drug into the reservoir layer. Alternatively, dissolving the drug in a suitable solvent or solvent mixture an applying the drug solution to the medical device provides for a substantially polymer-free drug layer.
[0054] Instead of introducing the drug as a solution, .the drug can be introduced as a colloid, such as a suspension in a solvent. Dispersing the drug in the solvent uses conventional techniques. Depending on a variety of factors, e.g., the nature of the drug, those having ordinary skill in the art can select the solvent for the suspension, as well as the quantity of the dispersed -drug. ' Some embodiments mix these suspensions with a polymer solution and apply the mixture onto the device, as described above. Alternatively, some embodiments apply the drug suspension to the device without mixing it with the polymer solution.
[0055] The drug-polymer layer can be applied directly onto at least a part of the medical device surface to serve as a reservoir for at least one active agent or. a drug. The optional primer layer can be applied between the device and the reservoir to improve polymer adhesion to the medical device. Some embodiments apply the topcoat layer over at least a portion of the reservoir layer, and the topcoat layer serves as a rate limiting membrane, which helps to control the rate of release of the drug.
[0056] Some drug releasing processes include at least two steps. First, the topcoat polymer absorbs the drug at the drug-polymer-topcoat interface. Next, the drug diffuses through the topcoat using empty spaces between the polymer molecules as diffusion pathways. Next, the drug arrives to the outer surface of the topcoat, and desorbs into the blood stream.
[0057] Invention polymers can be prepared by polycondensation reactions. First, the amine- terminated PEG is combined with terephthaloyl chloride with added pyridine to absorb the released HC1. After this block has reacted, the aliphatic diamine is added with additional teraphthaloyl chloride. Irganox 1330 can be added as an antioxidant to protect the PEG, as it is used in the synthesis of POLYACTIVE. Routes that use dimethyl terephthalate would avoid using the acid chloride. Application of heat and vacuum to remove the generated methanol will drive the polymerization. [0058] Of course, modifications to this synthesis must be made when Ll or L2 are not prepared to contain amide linkages, i.e. when Ll and L2 do not have the structure shown below. Such modifications are well within the skill level of one of ordinary skill in the art.
[0059] By making the PEG block large enough, and the copolymer random enough to keep the hard blocks small, the solubility can be adjusted.
Example Synthesis
Prophetic Example 1 : Synthesis of PEG-terephthalamide/butylene-terephthalamide block copoly(ether amide)
[0060] To a 500 ml, three necked round bottom flask equipped with nitrogen inlet, vacuum line, and mechanical stirrer is added Jeffamine ED-600 (37.36 g, 0.0623 moles) (shown below in Formula XVI). The flask is heated to 40 °C and a vacuum of less than 10 torr is drawn for 2 hours to remove any moisture. Nitrogen is introduced and the flask is cooled to room temperature. 125 ml of dry dimethyformamide is added with triethylamine (26 g, 0.257 moles), and 1 ,4-butanediamine (34.86 g, 0.172 moles). Terephthaloyl chloride (47.51 g, 0.234 moles) is slowly added to the reaction vessel and the solution slowly heated to 60 °C and allowed to react for 4 hours. After cooling, slow addition of the reaction mixture into 2 liters of stirred, deionized water will cause precipitation of the polymer, the formula of which is shown below in Formula XVII.
Figure imgf000022_0001
a+'c = 3.6; b = 9
ED-600
Formula XVI
Figure imgf000022_0002
Formula XVII
Prophetic Example 2: Synthesis of PEG-terephthalamideurethane/butylene- terephthalamideurethane block copoly(ether amide urethane)
[0061] To a 500 ml, three necked round bottom flask equipped with nitrogen inlet, vacuum line, and mechanical stirrer is added Jeffamine ED-2003 (36.67 g, 0.0183 moles) (shown below in Formula XVIII). The flask is heated to 60 °C and a vacuum of less than 10 torr is drawn for 2 hours to remove any moisture. Nitrogen is introduced and the flask is cooled to room temperature. Pyridine (20.88 g, 0.264 moles) is added, and 4-isocyanatobenzoyl chloride (43.64 g, 0.24 moles) is slowly added in a solution of 125 ml of dry dimethylformamide. The solution slowly heated to 60 °C and allowed to react for 4 hours. 1 ,4-butanediamine (19.61 g, 0.222 moles) is added and allowed to react at 60 °C for another 4 hours. After cooling, slow addition of the reaction mixture into 2 liters of stirred deionized water will cause precipitation of the polymer, which is shown below in Formulas Formula XIX-Formula XXII. Each of the Formulas Formula XIX-Formula XXII represent the same polymer, the only difference in the orientations of the benzoyl-derived group. For purposes of this disclosure listing one of formulas Formula XLX-Formula XXII represents each of Formula XIX-Formula XXII.
Figure imgf000023_0001
a+c = ~6; b = ~39
JEFF2003
Formula XVIII
Figure imgf000023_0002
Formula XIX
Figure imgf000023_0003
Formula XX
Figure imgf000023_0004
Formula XXI
Figure imgf000024_0001
Formula XXII
[0062] While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from the embodiments of this invention in its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of the embodiments of this invention.

Claims

What is claimed is:
1. A polymer comprising at least two different blocks wherein the blocks are selected from a) . at least one Ll block with the formula
- c >H4-(-< 0-C2H4- -L1-
or
Figure imgf000025_0001
and
b) at least one L2 block with the formula
Figure imgf000025_0002
' wherein c) the Ll blocks are the same or different; i) k are the same or different for each Ll block and ii) range from 6 to 460; and d) R i) are the same or different for each occurrence and ii) are 1-16 carbon (un)substituted, (un)branched alkyl, alkenyl, or alkynyl moieties, or 2-16 carbon (un)substituted, (unjbranched diol or triol oligomers; e) the L2 blocks are the same or different; i) j are the same or different for each L2 block and ii) range from 2 to 16; f) Ll and L2 are independently linkages with the following formula
Figure imgf000026_0001
i) wherein Y and Z are independently selected from the following moieties
0 0 H II 1! 1 -c— o — , •- -O — C — N-
0 H II 1 -C— N , -0 ,
H 0 0 1 II N — C — 0 , V U II». U
H 0 H 0 1 II 1 1! -N — C — . , or •— -c — s —
0 II provided that if Y and Z are the same, they are not • C 0-
2. The polymer of Claim 1 wherein R includes oligomers of ethylene glycol, propylene glycol (1,2- and 1,3 -substituted isomers), tetramethylene glycol (1,2-, 1,3-, 1,4-, and 2,3- substituted isomers), hexamethylene glycol (1,2-, 1,3-, 1,4- 1,5-, 1,6-, 2,3-, 2,4-, 2,5-,
3,
4- substituted isomers); or their mixtures.
The polymer of claim 1 wherein Y and Z are independently selected from
0 O H II I -C— O- -O — C — N-
Figure imgf000027_0001
H 0 H H O _'_|!_[!)_ or _ _4_0_
The polymer of claim 1 wherein Y and Z are independently selected from
O O H II I! I • C — 0 , • — 0 — C — N ,
Figure imgf000027_0002
H O H 0 H Ml I fl
5. The polymer of Claim 1 with the following formula C2,πH44 -O-C 2K1 '4 -L1- -CH, -L2- -T- m
-0-C2H4H— O-R— L1- -T- -CH, -L2- k-1 m n wherein . a) T represents the same or different, optional, biocompatible polymeric or non- polymeric linkage comprising from 1-100 atoms; b) 1 ranges from 0.005 to 2.0; c) m is 1 ; d) n ranges from 20 to 600; and e) R i) are the same or different for each occurrence and ii) are 1-16 carbon (un)substituted, (un)branched alkyl, alkenyl, or alkynyl moieties, or 2-16 carbon (un)substituted, (un)branched diol or triol oligomers.
6. The polymer of Claim 5 wherein R includes oligomers of ethylene glycol, propylene glycol (1,2- and 1,3 -substituted isomers), tetramethylene glycol (1,2-, 1,3-, 1,4-, and 2,3- substituted isomers), hexamethylene glycol (1,2-, 1,3-; 1,4- 1,5-, 1,6-, 2,3-, 2,4-, 2,5-, 3,4- substituted isomers); or their mixtures.
7. The polymer of Claim 5 wherein LT is at least one of polyethylene, polypropylene, polyisobutylene, polyisoprene, polybutene, poly(hexamethylene glycol), poly(tetramethylene glycol), polypropylene glycol), or their mixtures.
8. The polymer of Claim 7 wherein T has a molecular weight of 26 to 500 Daltons.
9. The polymer of Claim 8 wherein T connects into the polymer with one or more of the following linkages
O O H • C II — O , • — O — C II — N I - ,
O H II I -C — N- -o-
H O. O -N — C — O- II -o — c — o-
Figure imgf000029_0001
10. The polymer of claim 5 wherein Y and Z are independently selected from
Figure imgf000030_0001
O H • — C II — N 1 - •-0— ,
H 0 H H 0 • N 1 — C II- -N 1 , or #— N 1 — C II— 0
1 1. The polymer of claim 5 wherein Y and Z are independently selected from
0 O H II -c— o- II I -0 — C — N-
0 H II 1 -C — N-
H 0 H 0 H I II I N — C— -o — , or -N — C — N-
12. The polymer of Claim 5 wherein Ll and L2 are independently selected from any of the following linking groups
Figure imgf000031_0001
Figure imgf000031_0002
Figure imgf000031_0003
Figure imgf000031_0004
Figure imgf000031_0005
13. The polymer of Claim 12 wherein L 1 and L2 are the same.
14. The polymer of Claim 5 wherein Ll and L2 are selected from any of the following linking groups
Figure imgf000032_0001
Figure imgf000032_0002
15. The polymer of Claim 14 wherein Ll andL2 are the same.
16. The polymer of Claim 5 wherein Y and Z are esters, amides, urethanes, ureas, ethers, carbonates, or thioesters, provided that both Y and Z are not esters.
17. The polymer of Claim 5 wherein Y and Z are amides, urethanes, ureas, ethers, or carbonates.
18. The polymer of Claim 5 wherein Y and Z are amides, urethanes, or ureas.
19. The polymer of Claim 5 wherein 0-75% of Y and Z combined are
O II • — c — o — •
20. The polymer of Claim 5 wherein 0-50% of Y and Z combined are 0 II • — c— o — .
21. The polymer of Claim 5 wherein 0-25% of Y and Z combined are
0 II • — c— o — .
22. The polymer of Claim 5 wherein 0-5% of Y and Z combined are
• ■ O II • — c— o — ■
23. The polymer of Claim 5 wherein 90-99% of Y and Z. combined are
O • — c II— o — ■
24. The polymer of Claim 5 wherein 75-100% of Y and Z combined are
O H II I -C — N-
25. The polymer of Claim.5 wherein 50-100% of Y and Z combined are
O H II I • C^-N • •
26. The polymer of Claim 11 wherein 25-100%) of Y and Z combined are
O H -C II —. N I -
27. The polymer of claim 1 wherein a) Ll blocks have the following formula
Figure imgf000034_0001
or
Figure imgf000034_0002
b) L2 blocks have the following formula
Figure imgf000034_0003
28. The polymer of claim 1 wherein a) Ll blocks have one of the following formulas
O H II I -O-C2H4-] — 0-R — N-C-O- -C-N k-1
Figure imgf000035_0001
H 0 O H I II 11 1 -0-C2H4-j— O-R- -N-C- w -C-N- k-1
Figure imgf000035_0002
Figure imgf000035_0003
Figure imgf000035_0004
Figure imgf000035_0005
Figure imgf000036_0001
H 0 H O H 1 11 11 1 2H4— f 0— C2H4 -N-C- -C-N-l- and b) L2 blocks have one of the following formulas
Figure imgf000036_0002
29. A polymer comprising at least two blocks wherein a) the first block has the formula
Figure imgf000036_0003
or
Figure imgf000037_0001
i) k ranges from 6 to 460; and ii) 1 ranges from 0.003 to 0.60; b) the second block has the formula
Figure imgf000037_0002
i) j ranges from 2 to 30; and ii) m is 1 ; and wherein the weight average molecular weight of the polymer ranges from 38,000 to 188,000 Daltons.
30. A medical device comprising at Least one type-one polymer, wherein a type-one polymer is apolymer as described in claims 1, 4, 5, 7, 10, 13, 15, 24, 28, or 29.
31. The medical device of claim 30 wherein the type-one polymer is coated onto the surface of the device to form a layer of polymer.
32. The medical device of claim 30 further comprising another type-one polymer.
33. The medical device of claim 32 wherein the type-one polymer is disposed on the surface of the device to form a polymer layer and another type-one polymer is disposed on the polymer layer.
34. The medical device of claim 30 further comprising a type-two polymer, wherein type-two polymers are biocompatible polymers.
35. The medical device of claims 34 wherein type-two polymers are selected from polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide-co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3-hydroxybutyrate), poly(3-hydroxy valerate), poly(hydroxybutyrate-co-hydroxyvalerate), poly(tyrosine derived carbonates), poly yrosine arylates), poly(imino carbonates), .poly(trimethylene carbonate), poly(anhydrides), poly(orthoesters), poly(ester amides) or their mixtures.
36. The medical device of claim 30 comprising a mixture of the type-one and type-two polymers.
37. The medical device of claim 36 wherein the mixture is coated onto the surface of the medical device to create a layer.
38. The medical device of claim 34 comprising at least one anterior layer and one posterior layer wherein a) the anterior layer is a type-two polymer and the posterior layer is a type-one polymer; or
. b) the anterior layer is a type-one polymer and the posterior layer is a type-two polymer.
39. The medical device of claim 30 further comprising a drug;
40. The medical device of claim 34 further comprising a drug.
41. The medical device of claim 39 wherein the drug selected from antiproliferatives, antineoplastics, antiinflammatories, antiplateletes, anticoagulants, antifibrins, antithrombins, antimitotics, antibiotics, antioxidants, and their mixtures.
42. The medical device of claim 41 wherein the device is selected from self-expandable stents, balloon-expandable stents, stent-grafts, venous, arterial, or aortic grafts, vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular assist devices, artificial hearts, cardiopuhnonary by-pass circuits, blood oxygenatoirs, and endocardial leads.
43. A method for coating the medical device of Claim 30 wherein the type-one polymer is deposited in a layer of 0.5-500 microns thick onto the surface of the medical device.
44. A method for coating a medical device comprising a) applying at least one type-one polymer, wherein a type-one polymer is a polymer as described in claims 1, 4, 5, 7, 10 13, 15, 24, 28,, or 29, to the surface of the medical device; and b) optionally, applying a type-two polymer.
45. The method of Claim 44 wherein step a) comprises mixing a) at least one type-one polymer and b) at least one drug.
46. The method of Claim 44 wherein step a) comprises mixing a) at least one type-one polymer and b) at least one type-two polymer.
47. The medical device of Claim 30 a) wherein the device is selected from self-expandable stents, balloon-expandable stents, stent-grafts, venous, arterial, or aortic grafts, vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular - assist devices, artificial hearts, cardiopuhnonary by-pass circuits, blood oxygenators, and endocardial leads; b) wherein the device further comprises a drug; c) wherein the drug is selected from antiproliferatives, antineoplastics, antiinflammatories, antiplateletes, anticoagulants, antifϊbrins, antithrombins, antimitotics, antibiotics, antioxidants, and their mixtures; and d) wherein the type-one polymer is deposited in a layer of 0.5-500 microns thick onto the surface of the medical device.
48. The medical device of Claim 30 a) wherein the device is selected from self-expandable stents, balloon-expandable stents, stent-grafts, venous, arterial, or aortic grafts, vascular grafts, artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, guidewires, ventricular assist devices, artificial hearts, cardiopulmonary by-pass circuits, blood oxygenators, and endocardial leads; b) wherein the device further comprises a drug; c) wherein the drug selected from antiproliferatives, antineoplastics, antiinflammatories, antiplateletes, anticoagulants, antifibrins, antithrombins, antimitotics, antibiotics, antioxidants, and their mixtures; d) wherein the type-one polymer is deposited in a layer of 1 - 1000 microns thick onto the surface of the medical device; e) wherein the device further comprising a type-two polymer; and f) wherein type-two polymers are selected from polycaprolactone, poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-L-lactide), poly(glycolide), poly(D,L-lactide- co-glycolide), poly(dioxanone), poly(4-hydroxybutyrate), poly(3- hydrpxybutyrate), poly(3-hydroxy valerate), poly(hydrόxybutyrate-co- hydroxyvalerate), poly(tyrosine derived carbonates), poly(tyrosine arylates), poly(imino carbonates), poly(trimethylene carbonate), poly(anhydrides), poly(orthoesters), poly(ester amides) or their mixtures.
49. The polymer of Claim 1 with the following formula
Figure imgf000041_0001
50. The polymer of Claim 1 with the following formula
Figure imgf000041_0002
PCT/US2004/041205 2003-12-19 2004-12-09 Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents WO2005066241A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20040813517 EP1694743A1 (en) 2003-12-19 2004-12-09 Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
JP2006545750A JP2007518850A (en) 2003-12-19 2004-12-09 Biobeneficial polyamide / polyethylene glycol polymer for use with drug eluting stents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/741,214 US7435788B2 (en) 2003-12-19 2003-12-19 Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US10/741,214 2003-12-19

Publications (1)

Publication Number Publication Date
WO2005066241A1 true WO2005066241A1 (en) 2005-07-21

Family

ID=34678080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041205 WO2005066241A1 (en) 2003-12-19 2004-12-09 Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents

Country Status (4)

Country Link
US (5) US7435788B2 (en)
EP (1) EP1694743A1 (en)
JP (1) JP2007518850A (en)
WO (1) WO2005066241A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110508A2 (en) * 2004-04-30 2005-11-24 Advanced Cardiovascular Systems, Inc. Modulating properties of coatings on implantable devices
WO2005121264A2 (en) * 2004-06-03 2005-12-22 Advanced Cardiovascular Systems, Inc. Poly(ester amide) coating composition for implantable devices
WO2006074391A2 (en) * 2005-01-05 2006-07-13 Surmodics, Inc. Biodegradable coating compositions comprising blends
WO2006074406A2 (en) * 2005-01-05 2006-07-13 Surmodics, Inc. Biodegradable coating compositions including multiple layers
US8377107B2 (en) 2006-02-28 2013-02-19 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US8815274B2 (en) 2004-04-30 2014-08-26 Advanced Cardiovascular Systems, Inc. Poly(ester amides) for the control of agent-release from polymeric compositions
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
US7435788B2 (en) 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US7563324B1 (en) * 2003-12-29 2009-07-21 Advanced Cardiovascular Systems Inc. System and method for coating an implantable medical device
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US7390497B2 (en) 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8377462B2 (en) * 2005-07-29 2013-02-19 Advanced Cardiovascular Systems, Inc. PEA-TEMPO/PEA-BZ coatings for controlled delivery of drug from implantable medical devices
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8486135B2 (en) * 2006-06-01 2013-07-16 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from branched polymers
US8323676B2 (en) * 2008-06-30 2012-12-04 Abbott Cardiovascular Systems Inc. Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
US20090258028A1 (en) * 2006-06-05 2009-10-15 Abbott Cardiovascular Systems Inc. Methods Of Forming Coatings For Implantable Medical Devices For Controlled Release Of A Peptide And A Hydrophobic Drug
US20080124372A1 (en) 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US7771739B2 (en) * 2006-06-30 2010-08-10 Abbott Cardiovascular Systems Inc. Implantable medical devices comprising semi-crystalline poly(ester-amide)
US20080008736A1 (en) * 2006-07-06 2008-01-10 Thierry Glauser Random copolymers of methacrylates and acrylates
US20090181063A1 (en) * 2006-07-13 2009-07-16 Michael Huy Ngo Implantable medical device comprising a pro-healing poly(ester-amide)
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US20080175882A1 (en) * 2007-01-23 2008-07-24 Trollsas Mikael O Polymers of aliphatic thioester
US8262723B2 (en) * 2007-04-09 2012-09-11 Abbott Cardiovascular Systems Inc. Implantable medical devices fabricated from polymer blends with star-block copolymers
US10155881B2 (en) * 2007-05-30 2018-12-18 Abbott Cardiovascular Systems Inc. Substituted polycaprolactone for coating
US8252361B2 (en) * 2007-06-05 2012-08-28 Abbott Cardiovascular Systems Inc. Implantable medical devices for local and regional treatment
US9737638B2 (en) 2007-06-20 2017-08-22 Abbott Cardiovascular Systems, Inc. Polyester amide copolymers having free carboxylic acid pendant groups
US7927621B2 (en) 2007-06-25 2011-04-19 Abbott Cardiovascular Systems Inc. Thioester-ester-amide copolymers
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
US9814553B1 (en) 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
US20090306120A1 (en) * 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
US20090104241A1 (en) * 2007-10-23 2009-04-23 Pacetti Stephen D Random amorphous terpolymer containing lactide and glycolide
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US8128983B2 (en) * 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
US20090297584A1 (en) * 2008-04-18 2009-12-03 Florencia Lim Biosoluble coating with linear over time mass loss
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US20090285873A1 (en) * 2008-04-18 2009-11-19 Abbott Cardiovascular Systems Inc. Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide)
US8889172B1 (en) 2008-04-30 2014-11-18 Abbott Cardiovascular Systems Inc. Amorphous or semi-crystalline poly(ester amide) polymer with a high glass transition temperature
US8697113B2 (en) * 2008-05-21 2014-04-15 Abbott Cardiovascular Systems Inc. Coating comprising a terpolymer comprising caprolactone and glycolide
US8765162B2 (en) * 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
US20100047319A1 (en) * 2008-08-21 2010-02-25 Michael Huy Ngo Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8697110B2 (en) 2009-05-14 2014-04-15 Abbott Cardiovascular Systems Inc. Polymers comprising amorphous terpolymers and semicrystalline blocks
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
CA3186201A1 (en) * 2009-05-20 2010-11-25 Lyra Therapeutics, Inc. Self-expandable medical device comprising polymeric strands and coatings thereon
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
JP5312246B2 (en) * 2009-07-24 2013-10-09 キヤノン株式会社 Imaging apparatus and control method
KR101439627B1 (en) 2012-10-04 2014-09-11 삼성토탈 주식회사 Polylactic acid-polyalkylene glycol copolymer with fast crystallization rate and composition comprising the same
EP3288626A4 (en) * 2015-04-27 2019-01-23 Reflex Medical Inc. Systems and mehtods for sympathetic cardiopulmonary neuromodulation
US11246879B2 (en) 2016-02-09 2022-02-15 Tulai Therapeutics, Inc. Methods, agents, and devices for local neuromodulation of autonomic nerves
EP3478287A4 (en) 2016-06-29 2020-04-08 Tulavi Therapeutics, Inc. Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system
CA3105343A1 (en) 2018-07-02 2020-01-09 Corinne Bright Methods and devices for in situ formed nerve cap

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451954A2 (en) * 1990-04-10 1991-10-16 Huntsman Corporation Polyether amides and process for the preparation thereof
EP0451951A2 (en) * 1990-04-10 1991-10-16 Texaco Chemical Company Polyether amide from tetraethylene glycol diamine and terephthalic acid
US5837802A (en) * 1997-08-29 1998-11-17 H. B. Fuller Licensing & Financing, Inc. Fast setting water sensitive polyamides having a high Tg
WO1999013924A2 (en) * 1997-09-17 1999-03-25 Advanced Cardiovascular Systems, Inc. Polyether block amide catheter balloons
WO2001039810A1 (en) * 1999-12-01 2001-06-07 Advanced Cardiovascular Systems, Inc. Medical device balloon

Family Cites Families (284)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR732895A (en) * 1932-10-18 1932-09-25 Consortium Elektrochem Ind Articles spun in polyvinyl alcohol
US2386454A (en) 1940-11-22 1945-10-09 Bell Telephone Labor Inc High molecular weight linear polyester-amides
GB1137209A (en) 1965-04-05 1968-12-18 Eastman Kodak Co Polyesteramides
US3849514A (en) 1967-11-17 1974-11-19 Eastman Kodak Co Block polyester-polyamide copolymers
US3773737A (en) 1971-06-09 1973-11-20 Sutures Inc Hydrolyzable polymers of amino acid and hydroxy acids
US4329383A (en) 1979-07-24 1982-05-11 Nippon Zeon Co., Ltd. Non-thrombogenic material comprising substrate which has been reacted with heparin
US4226243A (en) 1979-07-27 1980-10-07 Ethicon, Inc. Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids
SU790725A1 (en) 1979-07-27 1983-01-23 Ордена Ленина Институт Элементоорганических Соединений Ан Ссср Process for preparing alkylaromatic polyimides
SU811750A1 (en) 1979-08-07 1983-09-23 Институт Физиологии Им.С.И.Бериташвили Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same
SU872531A1 (en) 1979-08-07 1981-10-15 Институт Физиологии Им.И.С.Бериташвили Ан Гсср Method of producing polyurethans
SU876663A1 (en) 1979-11-11 1981-10-30 Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср Method of producing polyarylates
DE2949064C2 (en) * 1979-12-06 1985-10-31 Chemische Werke Hüls AG, 4370 Marl Use of copolyether ester amides as hot melt adhesives for heat sealing textiles
SU1016314A1 (en) 1979-12-17 1983-05-07 Институт Физиологии Им.И.С.Бериташвили Process for producing polyester urethanes
US4343931A (en) 1979-12-17 1982-08-10 Minnesota Mining And Manufacturing Company Synthetic absorbable surgical devices of poly(esteramides)
US4529792A (en) 1979-12-17 1985-07-16 Minnesota Mining And Manufacturing Company Process for preparing synthetic absorbable poly(esteramides)
SU905228A1 (en) 1980-03-06 1982-02-15 Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср Method for preparing thiourea
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
DE3247755A1 (en) 1982-12-23 1984-06-28 Plate Bonn Gmbh, 5300 Bonn COPOLYETHERESTERAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR HOT SEALING TEXTILES
SU1293518A1 (en) 1985-04-11 1987-02-28 Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий Installation for testing specimen of cross-shaped structure
US4656242A (en) * 1985-06-07 1987-04-07 Henkel Corporation Poly(ester-amide) compositions
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4611051A (en) 1985-12-31 1986-09-09 Union Camp Corporation Novel poly(ester-amide) hot-melt adhesives
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
JPH0696023B2 (en) 1986-11-10 1994-11-30 宇部日東化成株式会社 Artificial blood vessel and method for producing the same
US5721131A (en) * 1987-03-06 1998-02-24 United States Of America As Represented By The Secretary Of The Navy Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells
US4800882A (en) * 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US6387379B1 (en) 1987-04-10 2002-05-14 University Of Florida Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like
US4894231A (en) 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
JP2561309B2 (en) 1988-03-28 1996-12-04 テルモ株式会社 Medical material and manufacturing method thereof
US4931287A (en) 1988-06-14 1990-06-05 University Of Utah Heterogeneous interpenetrating polymer networks for the controlled release of drugs
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US4977901A (en) 1988-11-23 1990-12-18 Minnesota Mining And Manufacturing Company Article having non-crosslinked crystallized polymer coatings
IL90193A (en) 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US5272012A (en) 1989-06-23 1993-12-21 C. R. Bard, Inc. Medical apparatus having protective, lubricious coating
US5971954A (en) 1990-01-10 1999-10-26 Rochester Medical Corporation Method of making catheter
US5496557A (en) 1990-01-30 1996-03-05 Akzo N.V. Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
US5306501A (en) * 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5298260A (en) * 1990-05-01 1994-03-29 Mediventures, Inc. Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
WO1991017724A1 (en) 1990-05-17 1991-11-28 Harbor Medical Devices, Inc. Medical device polymer
CA2038605C (en) 1990-06-15 2000-06-27 Leonard Pinchuk Crack-resistant polycarbonate urethane polymer prostheses and the like
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
WO1991019529A1 (en) 1990-06-15 1991-12-26 Cortrak Medical, Inc. Drug delivery apparatus and method
US5112457A (en) 1990-07-23 1992-05-12 Case Western Reserve University Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5163952A (en) 1990-09-14 1992-11-17 Michael Froix Expandable polymeric stent with memory and delivery apparatus and method
US5258020A (en) * 1990-09-14 1993-11-02 Michael Froix Method of using expandable polymeric stent with memory
US6248129B1 (en) 1990-09-14 2001-06-19 Quanam Medical Corporation Expandable polymeric stent with memory and delivery apparatus and method
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
GB9027793D0 (en) * 1990-12-21 1991-02-13 Ucb Sa Polyester-amides containing terminal carboxyl groups
US5489667A (en) * 1991-03-20 1996-02-06 Atochem Deutschland Gmbh Polyetheresteramides and process for making and using the same
HU222501B1 (en) * 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5599352A (en) 1992-03-19 1997-02-04 Medtronic, Inc. Method of making a drug eluting stent
GB9206736D0 (en) 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
US5219980A (en) 1992-04-16 1993-06-15 Sri International Polymers biodegradable or bioerodiable into amino acids
DE69325845T2 (en) 1992-04-28 2000-01-05 Terumo Corp Thermoplastic polymer composition and medical devices made therefrom
DE4224401A1 (en) 1992-07-21 1994-01-27 Pharmatech Gmbh New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd.
US5250652A (en) 1992-07-30 1993-10-05 Lever Brothers Company, Division Of Conopco, Inc. High loading water-dispersible UVA and/or UVB light-absorbing copolymer
FR2699168B1 (en) 1992-12-11 1995-01-13 Rhone Poulenc Chimie Method of treating a material comprising a polymer by hydrolysis.
EP0604022A1 (en) 1992-12-22 1994-06-29 Advanced Cardiovascular Systems, Inc. Multilayered biodegradable stent and method for its manufacture
US5824048A (en) 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US20020055710A1 (en) 1998-04-30 2002-05-09 Ronald J. Tuch Medical device for delivering a therapeutic agent and method of preparation
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
JPH0767895A (en) 1993-06-25 1995-03-14 Sumitomo Electric Ind Ltd Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
EG20321A (en) 1993-07-21 1998-10-31 Otsuka Pharma Co Ltd Medical material and process for producing the same
GB2281161B (en) 1993-08-04 1997-05-28 Fulcrum Communications Limited Optical data communications networks
DE4327024A1 (en) 1993-08-12 1995-02-16 Bayer Ag Thermoplastically processable and biodegradable aliphatic polyesteramides
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
WO1995010989A1 (en) * 1993-10-19 1995-04-27 Scimed Life Systems, Inc. Intravascular stent pump
US5723004A (en) 1993-10-21 1998-03-03 Corvita Corporation Expandable supportive endoluminal grafts
WO1995019796A1 (en) 1994-01-21 1995-07-27 Brown University Research Foundation Biocompatible implants
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
CA2190121A1 (en) 1994-03-15 1995-09-21 Edith Mathiowitz Polymeric gene delivery system
US5567410A (en) 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5670558A (en) 1994-07-07 1997-09-23 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
JP3654667B2 (en) * 1994-07-22 2005-06-02 生化学工業株式会社 Polypeptide, process for producing the same and DNA encoding the same
US5788979A (en) 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
US5516881A (en) 1994-08-10 1996-05-14 Cornell Research Foundation, Inc. Aminoxyl-containing radical spin labeling in polymers and copolymers
US5578073A (en) 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5649977A (en) 1994-09-22 1997-07-22 Advanced Cardiovascular Systems, Inc. Metal reinforced polymer stent
US5485496A (en) * 1994-09-22 1996-01-16 Cornell Research Foundation, Inc. Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties
FR2724938A1 (en) 1994-09-28 1996-03-29 Lvmh Rech POLYMERS FUNCTIONALIZED BY AMINO ACIDS OR AMINO ACID DERIVATIVES, THEIR USE AS SURFACTANTS, IN PARTICULAR, IN COSMETIC COMPOSITIONS AND IN PARTICULAR NAIL POLISH.
EP0785774B1 (en) * 1994-10-12 2001-01-31 Focal, Inc. Targeted delivery via biodegradable polymers
US5637113A (en) 1994-12-13 1997-06-10 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5569198A (en) 1995-01-23 1996-10-29 Cortrak Medical Inc. Microporous catheter
US5919570A (en) 1995-02-01 1999-07-06 Schneider Inc. Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices
US6017577A (en) 1995-02-01 2000-01-25 Schneider (Usa) Inc. Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5869127A (en) * 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5854376A (en) 1995-03-09 1998-12-29 Sekisui Kaseihin Kogyo Kabushiki Kaisha Aliphatic ester-amide copolymer resins
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US20020091433A1 (en) 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
RU2169742C2 (en) 1995-04-19 2001-06-27 Катаока Казунори Heterotelochelate block copolymer and method of preparation thereof
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5674242A (en) 1995-06-06 1997-10-07 Quanam Medical Corporation Endoprosthetic device with therapeutic compound
CA2178541C (en) * 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US5820917A (en) * 1995-06-07 1998-10-13 Medtronic, Inc. Blood-contacting medical device and method
US6010530A (en) * 1995-06-07 2000-01-04 Boston Scientific Technology, Inc. Self-expanding endoluminal prosthesis
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US5667767A (en) 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5723219A (en) 1995-12-19 1998-03-03 Talison Research Plasma deposited film networks
US5658995A (en) 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
DE19545678A1 (en) 1995-12-07 1997-06-12 Goldschmidt Ag Th Copolymers of polyamino acid esters
DK2111876T3 (en) * 1995-12-18 2011-12-12 Angiodevice Internat Gmbh Crosslinked polymer preparations and methods for their use
US6033582A (en) * 1996-01-22 2000-03-07 Etex Corporation Surface modification of medical implants
US6054553A (en) * 1996-01-29 2000-04-25 Bayer Ag Process for the preparation of polymers having recurring agents
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
US5610241A (en) * 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US5876433A (en) 1996-05-29 1999-03-02 Ethicon, Inc. Stent and method of varying amounts of heparin coated thereon to control treatment
US5874165A (en) 1996-06-03 1999-02-23 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto polymeric subtrates
NL1003459C2 (en) * 1996-06-28 1998-01-07 Univ Twente Copoly (ester amides) and copoly (ester urethanes).
US5711958A (en) 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US6060518A (en) 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
US5783657A (en) 1996-10-18 1998-07-21 Union Camp Corporation Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids
US6530951B1 (en) * 1996-10-24 2003-03-11 Cook Incorporated Silver implantable medical device
US6120491A (en) 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
DE19652037A1 (en) 1996-12-13 1998-06-18 Wolff Walsrode Ag Elastic films with improved biodegradability and processes for their production
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US5997517A (en) 1997-01-27 1999-12-07 Sts Biopolymers, Inc. Bonding layers for medical device surface coatings
DE69826639T2 (en) 1997-01-28 2005-10-06 United States Surgical Corp., Norwalk SURGICAL ARTICLES MADE FROM POLYESTERAMIDES WITH GROUPS DERIVED FROM AMINO ACIDS AND ALTERNATIVELY WITH GROUPS DERIVED FROM ALPHA HYDROXYLIC ACIDS
DE69828387T2 (en) 1997-01-28 2005-12-08 United States Surgical Corp., Norwalk POLYESTERAMIDE, ITS PRESENTATION AND SURGICAL FABRICATED SURGICAL ARTICLES
WO1998032779A1 (en) 1997-01-28 1998-07-30 United States Surgical Corporation Polyesteramide, its preparation and surgical devices fabricated therefrom
IL132120A0 (en) 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
US6240616B1 (en) 1997-04-15 2001-06-05 Advanced Cardiovascular Systems, Inc. Method of manufacturing a medicated porous metal prosthesis
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) * 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6056993A (en) 1997-05-30 2000-05-02 Schneider (Usa) Inc. Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel
US6110483A (en) 1997-06-23 2000-08-29 Sts Biopolymers, Inc. Adherent, flexible hydrogel and medicated coatings
US6211249B1 (en) * 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
US5980928A (en) 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
AU8901798A (en) * 1997-08-08 1999-03-01 Procter & Gamble Company, The Laundry detergent compositions with amino acid based polymers to provide appearance and integrity benefits to fabrics laundered therewith
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6120788A (en) 1997-10-16 2000-09-19 Bioamide, Inc. Bioabsorbable triglycolic acid poly(ester-amide)s
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
CN1248199A (en) 1997-12-24 2000-03-22 埃勒夫阿托化学有限公司 Multilayer structure comprising material coated with block polyamide and block hydrophilic copolymers
US6110188A (en) 1998-03-09 2000-08-29 Corvascular, Inc. Anastomosis method
US6258371B1 (en) 1998-04-03 2001-07-10 Medtronic Inc Method for making biocompatible medical article
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
US7658727B1 (en) 1998-04-20 2010-02-09 Medtronic, Inc Implantable medical device with enhanced biocompatibility and biostability
EP1555036B1 (en) * 1998-04-27 2010-05-05 Surmodics Inc. Bioactive agent release coating
US20020188037A1 (en) 1999-04-15 2002-12-12 Chudzik Stephen J. Method and system for providing bioactive agent release coating
US6113629A (en) 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
KR100314496B1 (en) 1998-05-28 2001-11-22 윤동진 Non-thrombogenic heparin derivatives, process for preparation and use thereof
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
WO2000010622A1 (en) * 1998-08-20 2000-03-02 Cook Incorporated Coated implantable medical device
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6335029B1 (en) * 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6011125A (en) * 1998-09-25 2000-01-04 General Electric Company Amide modified polyesters
US6530950B1 (en) * 1999-01-12 2003-03-11 Quanam Medical Corporation Intraluminal stent having coaxial polymer member
US6316585B1 (en) 1999-01-18 2001-11-13 Council Of Scientific And Industrial Research Process for the preparation of enzymatically degradable polymers
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6143354A (en) 1999-02-08 2000-11-07 Medtronic Inc. One-step method for attachment of biomolecules to substrate surfaces
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6283947B1 (en) 1999-07-13 2001-09-04 Advanced Cardiovascular Systems, Inc. Local drug delivery injection catheter
US6494862B1 (en) * 1999-07-13 2002-12-17 Advanced Cardiovascular Systems, Inc. Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway
US6177523B1 (en) * 1999-07-14 2001-01-23 Cardiotech International, Inc. Functionalized polyurethanes
US20040029952A1 (en) * 1999-09-03 2004-02-12 Yung-Ming Chen Ethylene vinyl alcohol composition and coating
US6749626B1 (en) 2000-03-31 2004-06-15 Advanced Cardiovascular Systems, Inc. Actinomycin D for the treatment of vascular disease
US6379381B1 (en) * 1999-09-03 2002-04-30 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6713119B2 (en) * 1999-09-03 2004-03-30 Advanced Cardiovascular Systems, Inc. Biocompatible coating for a prosthesis and a method of forming the same
US6287628B1 (en) 1999-09-03 2001-09-11 Advanced Cardiovascular Systems, Inc. Porous prosthesis and a method of depositing substances into the pores
US6503556B2 (en) * 2000-12-28 2003-01-07 Advanced Cardiovascular Systems, Inc. Methods of forming a coating for a prosthesis
US6503954B1 (en) * 2000-03-31 2003-01-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing actinomycin D and a method of forming the same
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6759054B2 (en) 1999-09-03 2004-07-06 Advanced Cardiovascular Systems, Inc. Ethylene vinyl alcohol composition and coating
US6203551B1 (en) * 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6613432B2 (en) * 1999-12-22 2003-09-02 Biosurface Engineering Technologies, Inc. Plasma-deposited coatings, devices and methods
US6908624B2 (en) 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
AU2599501A (en) 1999-12-29 2001-07-09 Advanced Cardiovascular Systems Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
JP4473390B2 (en) 2000-01-07 2010-06-02 川澄化学工業株式会社 Stent and stent graft
US6703040B2 (en) * 2000-01-11 2004-03-09 Intralytix, Inc. Polymer blends as biodegradable matrices for preparing biocomposites
US6379382B1 (en) 2000-03-13 2002-04-30 Jun Yang Stent having cover with drug delivery capability
US6527801B1 (en) 2000-04-13 2003-03-04 Advanced Cardiovascular Systems, Inc. Biodegradable drug delivery material for stent
US20020007215A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20020007214A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020005206A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Antiproliferative drug and delivery device
US20020007213A1 (en) * 2000-05-19 2002-01-17 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US6395326B1 (en) 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6673385B1 (en) * 2000-05-31 2004-01-06 Advanced Cardiovascular Systems, Inc. Methods for polymeric coatings stents
US20020020011A1 (en) * 2000-06-19 2002-02-21 John Arout Portable, strong and light weight pool/spa element
US6585765B1 (en) 2000-06-29 2003-07-01 Advanced Cardiovascular Systems, Inc. Implantable device having substances impregnated therein and a method of impregnating the same
US20020077693A1 (en) 2000-12-19 2002-06-20 Barclay Bruce J. Covered, coiled drug delivery stent and method
US6555157B1 (en) * 2000-07-25 2003-04-29 Advanced Cardiovascular Systems, Inc. Method for coating an implantable device and system for performing the method
WO2002009768A2 (en) * 2000-07-27 2002-02-07 Rutgers, The State University Therapeutic polyesters and polyamides
US6451373B1 (en) 2000-08-04 2002-09-17 Advanced Cardiovascular Systems, Inc. Method of forming a therapeutic coating onto a surface of an implantable prosthesis
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US6585926B1 (en) 2000-08-31 2003-07-01 Advanced Cardiovascular Systems, Inc. Method of manufacturing a porous balloon
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6254632B1 (en) 2000-09-28 2001-07-03 Advanced Cardiovascular Systems, Inc. Implantable medical device having protruding surface structures for drug delivery and cover attachment
US20020051730A1 (en) 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US20020111590A1 (en) 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US6506437B1 (en) * 2000-10-17 2003-01-14 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device having depots formed in a surface thereof
US6558733B1 (en) 2000-10-26 2003-05-06 Advanced Cardiovascular Systems, Inc. Method for etching a micropatterned microdepot prosthesis
US6758859B1 (en) 2000-10-30 2004-07-06 Kenny L. Dang Increased drug-loading and reduced stress drug delivery device
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
US20020082679A1 (en) 2000-12-22 2002-06-27 Avantec Vascular Corporation Delivery or therapeutic capable agents
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US6544543B1 (en) 2000-12-27 2003-04-08 Advanced Cardiovascular Systems, Inc. Periodic constriction of vessels to treat ischemic tissue
US6540776B2 (en) * 2000-12-28 2003-04-01 Advanced Cardiovascular Systems, Inc. Sheath for a prosthesis and methods of forming the same
US6663662B2 (en) 2000-12-28 2003-12-16 Advanced Cardiovascular Systems, Inc. Diffusion barrier layer for implantable devices
US20020087123A1 (en) 2001-01-02 2002-07-04 Hossainy Syed F.A. Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices
US6544223B1 (en) 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
US6544582B1 (en) * 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Method and apparatus for coating an implantable device
US6645195B1 (en) 2001-01-05 2003-11-11 Advanced Cardiovascular Systems, Inc. Intraventricularly guided agent delivery system and method of use
US6740040B1 (en) 2001-01-30 2004-05-25 Advanced Cardiovascular Systems, Inc. Ultrasound energy driven intraventricular catheter to treat ischemia
US20030032767A1 (en) * 2001-02-05 2003-02-13 Yasuhiro Tada High-strength polyester-amide fiber and process for producing the same
WO2002064014A2 (en) 2001-02-09 2002-08-22 Endoluminal Therapeutics, Inc. Endomural therapy
DE10107795B4 (en) 2001-02-13 2014-05-15 Berlex Ag Vascular support with a basic body, method for producing the vascular support, apparatus for coating the vascular support
WO2002072014A2 (en) * 2001-03-08 2002-09-19 Volcano Therapeutics, Inc. Medical devices, compositions and methods for treating vulnerable plaque
US7241832B2 (en) 2002-03-01 2007-07-10 bio-tec Biologische Naturverpackungen GmbH & Co., KG Biodegradable polymer blends for use in making films, sheets and other articles of manufacture
US6623448B2 (en) 2001-03-30 2003-09-23 Advanced Cardiovascular Systems, Inc. Steerable drug delivery device
US6645135B1 (en) 2001-03-30 2003-11-11 Advanced Cardiovascular Systems, Inc. Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance
US6780424B2 (en) 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US6625486B2 (en) 2001-04-11 2003-09-23 Advanced Cardiovascular Systems, Inc. Method and apparatus for intracellular delivery of an agent
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US6712845B2 (en) * 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
EP1383504A1 (en) * 2001-04-26 2004-01-28 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
US6660034B1 (en) 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
US6656506B1 (en) * 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
US7651695B2 (en) 2001-05-18 2010-01-26 Advanced Cardiovascular Systems, Inc. Medicated stents for the treatment of vascular disease
US6605154B1 (en) 2001-05-31 2003-08-12 Advanced Cardiovascular Systems, Inc. Stent mounting device
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US6743462B1 (en) 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US6666880B1 (en) 2001-06-19 2003-12-23 Advised Cardiovascular Systems, Inc. Method and system for securing a coated stent to a balloon catheter
US6572644B1 (en) 2001-06-27 2003-06-03 Advanced Cardiovascular Systems, Inc. Stent mounting device and a method of using the same to coat a stent
US6695920B1 (en) 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US6673154B1 (en) * 2001-06-28 2004-01-06 Advanced Cardiovascular Systems, Inc. Stent mounting device to coat a stent
US6565659B1 (en) 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US6527863B1 (en) 2001-06-29 2003-03-04 Advanced Cardiovascular Systems, Inc. Support device for a stent and a method of using the same to coat a stent
US6706013B1 (en) * 2001-06-29 2004-03-16 Advanced Cardiovascular Systems, Inc. Variable length drug delivery catheter
US6656216B1 (en) * 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
EP1273314A1 (en) 2001-07-06 2003-01-08 Terumo Kabushiki Kaisha Stent
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20030083739A1 (en) 2001-09-24 2003-05-01 Robert Cafferata Rational drug therapy device and methods
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US6753071B1 (en) 2001-09-27 2004-06-22 Advanced Cardiovascular Systems, Inc. Rate-reducing membrane for release of an agent
US20030059520A1 (en) * 2001-09-27 2003-03-27 Yung-Ming Chen Apparatus for regulating temperature of a composition and a method of coating implantable devices
US20030073961A1 (en) * 2001-09-28 2003-04-17 Happ Dorrie M. Medical device containing light-protected therapeutic agent and a method for fabricating thereof
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7585516B2 (en) 2001-11-12 2009-09-08 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
US6709514B1 (en) * 2001-12-28 2004-03-23 Advanced Cardiovascular Systems, Inc. Rotary coating apparatus for coating implantable medical devices
US20040054104A1 (en) 2002-09-05 2004-03-18 Pacetti Stephen D. Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol)
US20040063805A1 (en) 2002-09-19 2004-04-01 Pacetti Stephen D. Coatings for implantable medical devices and methods for fabrication thereof
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
US7056591B1 (en) 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
DE10345907B4 (en) 2003-10-02 2007-01-25 Minebea Co., Ltd. Hydrodynamic bearing, spindle motor and hard disk drive
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8192752B2 (en) 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7220816B2 (en) 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US8685431B2 (en) 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US20050208093A1 (en) 2004-03-22 2005-09-22 Thierry Glauser Phosphoryl choline coating compositions
US20050265960A1 (en) 2004-05-26 2005-12-01 Pacetti Stephen D Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US20050271700A1 (en) 2004-06-03 2005-12-08 Desnoyer Jessica R Poly(ester amide) coating composition for implantable devices
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US7166680B2 (en) 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451954A2 (en) * 1990-04-10 1991-10-16 Huntsman Corporation Polyether amides and process for the preparation thereof
EP0451951A2 (en) * 1990-04-10 1991-10-16 Texaco Chemical Company Polyether amide from tetraethylene glycol diamine and terephthalic acid
US5837802A (en) * 1997-08-29 1998-11-17 H. B. Fuller Licensing & Financing, Inc. Fast setting water sensitive polyamides having a high Tg
WO1999013924A2 (en) * 1997-09-17 1999-03-25 Advanced Cardiovascular Systems, Inc. Polyether block amide catheter balloons
WO2001039810A1 (en) * 1999-12-01 2001-06-07 Advanced Cardiovascular Systems, Inc. Medical device balloon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOUMA K ET AL: "POLYETHER-AMIDE SEGMENTED COPOLYMERS BASED ON ETHYLENE TEREPHTHALAMIDE UNITS OF UNIFORM LENGTH", JOURNAL OF APPLIED POLYMER SCIENCE, JOHN WILEY AND SONS INC. NEW YORK, US, vol. 80, no. 8, 23 May 2001 (2001-05-23), pages 1173 - 1180, XP001050928, ISSN: 0021-8995 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005110508A2 (en) * 2004-04-30 2005-11-24 Advanced Cardiovascular Systems, Inc. Modulating properties of coatings on implantable devices
WO2005110508A3 (en) * 2004-04-30 2006-05-26 Advanced Cardiovascular System Modulating properties of coatings on implantable devices
US8815274B2 (en) 2004-04-30 2014-08-26 Advanced Cardiovascular Systems, Inc. Poly(ester amides) for the control of agent-release from polymeric compositions
WO2005121264A2 (en) * 2004-06-03 2005-12-22 Advanced Cardiovascular Systems, Inc. Poly(ester amide) coating composition for implantable devices
WO2005121264A3 (en) * 2004-06-03 2007-02-15 Advanced Cardiovascular System Poly(ester amide) coating composition for implantable devices
WO2006074406A3 (en) * 2005-01-05 2006-12-21 Surmodics Inc Biodegradable coating compositions including multiple layers
WO2006074391A3 (en) * 2005-01-05 2006-12-14 Surmodics Inc Biodegradable coating compositions comprising blends
WO2006074406A2 (en) * 2005-01-05 2006-07-13 Surmodics, Inc. Biodegradable coating compositions including multiple layers
WO2006074391A2 (en) * 2005-01-05 2006-07-13 Surmodics, Inc. Biodegradable coating compositions comprising blends
US8377107B2 (en) 2006-02-28 2013-02-19 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US8377499B2 (en) 2006-02-28 2013-02-19 Abbott Cardiovascular Systems Inc. Methods of forming Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US8389044B2 (en) 2006-02-28 2013-03-05 Advanced Cardiovascular Systems, Inc. Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US8865189B2 (en) 2006-02-28 2014-10-21 Abbott Cardiovascular Systems Inc. Poly(ester amide)-based drug delivery systems

Also Published As

Publication number Publication date
US20100297211A1 (en) 2010-11-25
US20090012243A1 (en) 2009-01-08
US20090012259A1 (en) 2009-01-08
JP2007518850A (en) 2007-07-12
US20090012606A1 (en) 2009-01-08
US7786249B2 (en) 2010-08-31
US7879953B2 (en) 2011-02-01
US7772359B2 (en) 2010-08-10
US20050137381A1 (en) 2005-06-23
US7632914B2 (en) 2009-12-15
EP1694743A1 (en) 2006-08-30
US7435788B2 (en) 2008-10-14

Similar Documents

Publication Publication Date Title
US7435788B2 (en) Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US8685431B2 (en) Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
EP1694373B1 (en) Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
EP1778764B1 (en) Coatings for implantable devices comprising poly(hydroxy-alkanoates) and diacid linkages
US7455907B2 (en) Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7378106B2 (en) Biologically absorbable coatings for implantable devices and methods for fabricating the same
US20060115449A1 (en) Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US20080175882A1 (en) Polymers of aliphatic thioester
US20140377325A1 (en) Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004813517

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006545750

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2004813517

Country of ref document: EP